

University of Dundee

## Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception

Cameron, Sharon T.; Glasier, Anna; McDaid, Lisa; Radley, Andrew; Patterson, Susan; Baraitser, Paula

*Published in:*  
Health technology assessment (Winchester, England)

*DOI:*  
[10.3310/hta25270](https://doi.org/10.3310/hta25270)

*Publication date:*  
2021

*Licence:*  
UK Government Non-Commercial Licence

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Cameron, S. T., Glasier, A., McDaid, L., Radley, A., Patterson, S., Baraitser, P., Stephenson, J., Gilson, R., Battison, C., Cowle, K., Vadiveloo, T., Johnstone, A., Morelli, A., Goulao, B., Forrest, M., McDonald, A., & Norrie, J. (2021). Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT. *Health technology assessment (Winchester, England)*, 25(27), 1-120. <https://doi.org/10.3310/hta25270>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.


## Health Technology Assessment

Volume 25 • Issue 27 • May 2021

ISSN 1366-5278

# Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT

*Sharon T Cameron, Anna Glasier, Lisa McDaid, Andrew Radley, Susan Patterson,  
Paula Baraitser, Judith Stephenson, Richard Gilson, Claire Battison, Kathleen Cowle,  
Thenmalar Vadiveloo, Anne Johnstone, Alessandra Morelli, Beatriz Goulao,  
Mark Forrest, Alison McDonald and John Norrie*





# Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT

Sharon T Cameron<sup>id,1,2\*</sup> Anna Glasier<sup>id,1</sup> Lisa McDaid<sup>id,3,4</sup>  
Andrew Radley<sup>id,5,6</sup> Susan Patterson<sup>id,4</sup> Paula Baraitser<sup>id,7</sup>  
Judith Stephenson<sup>id,8</sup> Richard Gilson<sup>id,9</sup> Claire Battison<sup>id,10</sup>  
Kathleen Cowle,<sup>11</sup> Thenmalar Vadiveloo<sup>id,12</sup>  
Anne Johnstone<sup>id,1</sup> Alessandra Morelli<sup>id,7</sup>  
Beatriz Goulao<sup>id,12</sup> Mark Forrest<sup>id,12</sup> Alison McDonald<sup>id,12</sup>  
and John Norrie<sup>id,10</sup>

<sup>1</sup>Obstetrics and Gynaecology, University of Edinburgh, Edinburgh, UK

<sup>2</sup>Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK

<sup>3</sup>Institute for Social Science Research, The University of Queensland, Brisbane, QLD, Australia

<sup>4</sup>Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK

<sup>5</sup>Directorate of Public Health, NHS Tayside, Dundee, UK

<sup>6</sup>Division of Cardiovascular Medicines and Diabetes, Ninewells Hospital and Medical School, Dundee, UK

<sup>7</sup>Department of Sexual Health, King's College Hospital NHS Foundation Trust, London, UK

<sup>8</sup>Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

<sup>9</sup>Institute for Global Health, University College London, London, UK

<sup>10</sup>Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK

<sup>11</sup>Community pharmacy, NHS Forth Valley, UK

<sup>12</sup>Health Services Research Unit, University of Aberdeen, Aberdeen, UK

\*Corresponding author

**Declared competing interests of authors:** Anna Glasier is a member of the HRA Pharma's (London, UK) scientific advisory board. Lisa McDaid and Susan Patterson are funded by the UK Medical Research Council (London, UK) and Scottish Government Chief Scientist Office (Edinburgh, UK) at the Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, University of Glasgow (Glasgow, UK) (MC\_UU\_12017/11, SPHSU11). Andrew Radley holds research grants, educational grants and consultancy with Gilead Sciences, Inc. (Foster City, CA, USA), research grants from Roche (Basel, Switzerland) and



Bristol Myers Squibb™ (New York, NY, USA), and educational grants from AbbVie (North Chicago, IL, USA). Paula Baraitser is a clinical director of the not-for profit community interest company SH:24 (London, UK), which provides online sexual health services in partnership with the NHS. Kathleen Cowle was an employee of Boots UK (Nottingham, UK) during the course of the study. Alessandra Morelli was a clinical bank midwife of the not-for-profit community interest company SH:24 (October 2019–January 2021). She is also a research midwife at the University of Oxford (Oxford, UK). John Norrie is deputy chairperson of the National Institute for Health Research Health Technology Assessment General Board Committee. He was a member of the Health Technology Assessment and Efficacy and Mechanism Evaluation Editorial Board (2014–19).

Published May 2021

DOI: 10.3310/hta25270

This report should be referenced as follows:

Cameron ST, Glasier A, McDaid L, Radley A, Patterson S, Baraitser P, *et al.* Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT. *Health Technol Assess* 2021;**25**(27).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus*/MEDLINE, *Excerpta Medica*/EMBASE, *Science Citation Index Expanded* (SciSearch®) and *Current Contents*®/Clinical Medicine.



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.370

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/113/01. The contractual start date was in April 2017. The draft report began editorial review in July 2020 and was accepted for publication in January 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2021. This work was produced by Cameron *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT

Sharon T Cameron<sup>1,2\*</sup> Anna Glasier<sup>1</sup> Lisa McDaid<sup>3,4</sup>  
Andrew Radley<sup>5,6</sup> Susan Patterson<sup>4</sup> Paula Baraitser<sup>7</sup>  
Judith Stephenson<sup>8</sup> Richard Gilson<sup>9</sup> Claire Battison<sup>10</sup>  
Kathleen Cowle<sup>11</sup> Thenmalar Vadiveloo<sup>12</sup> Anne Johnstone<sup>1</sup>  
Alessandra Morelli<sup>7</sup> Beatriz Goulao<sup>12</sup> Mark Forrest<sup>12</sup>  
Alison McDonald<sup>12</sup> and John Norrie<sup>10</sup>

<sup>1</sup>Obstetrics and Gynaecology, University of Edinburgh, Edinburgh, UK

<sup>2</sup>Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK

<sup>3</sup>Institute for Social Science Research, The University of Queensland, Brisbane, QLD, Australia

<sup>4</sup>Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK

<sup>5</sup>Directorate of Public Health, NHS Tayside, Dundee, UK

<sup>6</sup>Division of Cardiovascular Medicines and Diabetes, Ninewells Hospital and Medical School, Dundee, UK

<sup>7</sup>Department of Sexual Health, King's College Hospital NHS Foundation Trust, London, UK

<sup>8</sup>Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

<sup>9</sup>Institute for Global Health, University College London, London, UK

<sup>10</sup>Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK

<sup>11</sup>Community pharmacy, NHS Forth Valley, UK

<sup>12</sup>Health Services Research Unit, University of Aberdeen, Aberdeen, UK

\*Corresponding author [sharon.cameron@ed.ac.uk](mailto:sharon.cameron@ed.ac.uk)

**Introduction:** Unless women start effective contraception after using emergency contraception, they remain at risk of unintended pregnancy. Most women in the UK obtain emergency contraception from community pharmacies that are unable to provide ongoing contraception (apart from barrier methods which have high failure rates). This means that women need an appointment with a general practitioner or at a sexual and reproductive health clinic. We conducted a pragmatic cluster randomised cohort crossover trial to determine whether or not pharmacist provision of a bridging supply of a progestogen-only pill plus the invitation to attend a sexual and reproductive health clinic resulted in increased subsequent use of effective contraception (hormonal or intrauterine).

**Methods:** Twenty-nine pharmacies in three UK cities recruited women receiving emergency contraception (levonorgestrel). In the intervention, women received a 3-month supply of the progestogen-only pill (75 µg of desogestrel) plus a card that provided rapid access to a local sexual and reproductive health clinic. In the control arm, pharmacists advised women to attend their usual contraceptive provider. The primary outcome was reported use of an effective contraception (hormonal and intrauterine methods) at 4 months. Process evaluation was also conducted to inform any future implementation.

**Results:** The study took place December 2017 and June 2019 and recruited 636 women to the intervention ( $n = 316$ ) and control groups ( $n = 320$ ). There were no statistically significant differences in demographic characteristics between the groups. Four-month follow-up data were available for 406 participants: 63% (198/315) of the control group and 65% (208/318) of the intervention group. The proportion of participants reporting use of effective contraception was 20.1% greater (95% confidence interval 5.2% to 35.0%) in the intervention group (58.4%, 95% confidence interval 48.6% to 68.2%) than in the control group (40.5%, 95% confidence interval 29.7% to 51.3%) (adjusted for recruitment period, treatment arm and centre;  $p = 0.011$ ). The proportion of women using effective contraception remained statistically significantly larger, when adjusted for age, current sexual relationship and history of past use of effective contraception, and was robust to the missing data. There were no serious adverse events.

**Conclusion:** Provision of a bridging supply of the progestogen-only pill with emergency contraception from a pharmacist and the invitation to a sexual and reproductive health clinic resulted in a significant increase in self-reported subsequent use of effective contraception. This simple intervention has the potential to prevent more unintended pregnancies for women after emergency contraception.

**Trial registration:** Current Controlled Trials ISRCTN70616901.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 27. See the NIHR Journals Library website for further project information.

# Contents

List of tables	xi
List of figures	xiii
List of boxes	xv
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
<b>Chapter 1 Introduction</b>	<b>1</b>
Background	1
Rationale for study	2
<b>Chapter 2 Methods</b>	<b>3</b>
Study design	3
Participants	3
Procedures	4
Outcomes	4
Sample size	4
Randomisation	5
Statistical analysis	5
Summary of changes to the protocol	6
Ethics	6
<b>Chapter 3 Results</b>	<b>9</b>
Recruitment and participant flow	9
Four-month follow-up	11
Primary outcome: effective contraception use at 4 months	13
Contraceptive use and long-acting reversible contraception use at 4 months	13
Rapid-access card and sexual and reproductive health clinic utilisation	17
Pregnancies in the 4 months since emergency contraception	17
<b>Chapter 4 Mystery shopper exercise</b>	<b>21</b>
Mystery shopper exercise	21
Results	21
Discussion	22
<b>Chapter 5 Process evaluation</b>	<b>25</b>
Methods: data sources and analysis	25
<i>Qualitative interviews with pharmacists, sexual and reproductive health providers and participants</i>	25
<i>Monitoring of pharmacy selection and observations of training</i>	28
<i>Monitoring of contemporaneous events</i>	29
<i>Quantitative data collected as part of the main study</i>	29
<i>Researcher field notes and meeting minutes</i>	29

Synthesis of multiple data sources	29
Implementation	29
<i>Pharmacist and sexual and reproductive health provider acceptability of the intervention</i>	29
<i>Acceptability of taking part in a research study</i>	30
Pharmacist and sexual and reproductive health provider awareness of the study and preparedness to deliver	31
<i>Pharmacists' perceptions of and satisfaction with training</i>	31
<i>Awareness in sexual and reproductive health centres</i>	32
<i>Fidelity of intervention delivery</i>	32
<i>Mechanisms of impact: participants' experiences of bridging and impacts on contraceptive practices</i>	36
<i>Mechanisms of change: access, knowledge, confidence and self-efficacy</i>	36
<i>Facilitators of and barriers to continued uptake of routine contraception</i>	38
<i>Why did participants remain on effective contraception?</i>	38
<i>Barriers to continued uptake of effective contraception</i>	39
<i>The impact of context on the Bridge-it study implementation and outcomes</i>	41
<i>Changing contraceptive guidelines and potential impact on policy</i>	43
Process evaluation summary and key implications	43
<i>Summary of findings</i>	43
Key learning and implications	44
<i>Why did the intervention work?</i>	44
<i>Implications for wider implementation</i>	45
<b>Chapter 6 Discussion of the Bridge-it study</b>	<b>47</b>
Interpretation	47
<i>Why did the intervention work?</i>	47
<i>Did advice from the pharmacist play a role?</i>	47
Generalisability and limitations	48
Overall evidence	49
Recommendations for research	49
Implications for decision-makers	49
<i>What if offering a 3-month supply of the progestogen-only pill with emergency contraception became standard practice throughout the UK?</i>	49
<b>Chapter 7 Conclusions</b>	<b>51</b>
Impact of patient and public involvement, challenges of patient and public involvement and lessons learnt	51
<i>Pre-funding study design and protocol development</i>	51
<i>Mystery shopper exercise</i>	51
<i>Trial Steering Committee and key project decisions</i>	51
<i>Dissemination</i>	51
<b>Acknowledgements</b>	<b>53</b>
<b>References</b>	<b>57</b>
<b>Appendix 1 Supplemental table</b>	<b>61</b>
<b>Appendix 2 Process evaluation topic guides</b>	<b>67</b>
<b>Appendix 3 Baseline questionnaire</b>	<b>75</b>
<b>Appendix 4 Four-month questionnaire for control group</b>	<b>77</b>
<b>Appendix 5 Four-month questionnaire for intervention group</b>	<b>85</b>

# List of tables

<b>TABLE 1</b> Reasons for ineligibility after screening ( $n = 490$ women)	<b>10</b>
<b>TABLE 2</b> Characteristics of participants at recruitment	<b>11</b>
<b>TABLE 3</b> Characteristics (at baseline) of responders and non-responders at follow-up	<b>12</b>
<b>TABLE 4</b> Primary analysis for cluster-level models (outcome = percentage with effective contraception use)	<b>13</b>
<b>TABLE 5</b> Sensitivity analysis for cluster-level models (outcome = percentage of participants with effective contraception use)	<b>14</b>
<b>TABLE 6</b> Sensitivity analysis for hierarchical models [outcome = use of effective contraception (binary)]	<b>14</b>
<b>TABLE 7</b> Contraceptive use at the 4-month follow-up	<b>14</b>
<b>TABLE 8</b> Reasons for non-use of effective contraception at 4 months	<b>15</b>
<b>TABLE 9</b> Provision of contraceptive advice by community pharmacist	<b>15</b>
<b>TABLE 10</b> Use of POP by the intervention group	<b>16</b>
<b>TABLE 11</b> Uptake of rapid access to the SRH clinic	<b>17</b>
<b>TABLE 12</b> Data from the SRH clinic databases	<b>19</b>
<b>TABLE 13</b> Information provided by community pharmacist	<b>22</b>
<b>TABLE 14</b> The Bridge-it study process evaluation framework	<b>26</b>
<b>TABLE 15</b> Intervention interview participant characteristics	<b>28</b>
<b>TABLE 16</b> Process evaluation data integration table	<b>61</b>



# List of figures

<b>FIGURE 1</b> Consolidated Standards of Reporting Trials (CONSORT) flow chart	<b>9</b>
<b>FIGURE 2</b> Participant flow chart	<b>11</b>
<b>FIGURE 3</b> Process evaluation flow chart	<b>27</b>
<b>FIGURE 4</b> A flow chart of pharmacist training and support for delivering the Bridge-it study	<b>30</b>





# List of boxes

<b>BOX 1</b> Summary of changes to protocol	<b>6</b>
<b>BOX 2</b> Inclusion and exclusion criteria	<b>10</b>
<b>BOX 3</b> Free-text comments from mystery shoppers	<b>22</b>
<b>BOX 4</b> Key learning for future implementation 1	<b>36</b>
<b>BOX 5</b> Key learning for future implementation 2	<b>41</b>
<b>BOX 6</b> Key learning for future implementation 3	<b>44</b>



## List of abbreviations

CI	confidence interval	PGD	patient group direction
DMC	Data Monitoring Committee	POP	progestogen-only pill
EC	emergency contraception	PPI	patient and public involvement
GP	general practitioner	SD	standard deviation
LARC	long-acting reversible contraception	SRH	sexual and reproductive health
LNG	levonorgestrel	TSC	Trial Steering Committee
NIHR	National Institute for Health Research		



## Plain English summary

The emergency contraceptive pill can prevent pregnancy following unprotected sex or a burst condom; however, unless women start a regular method of contraception they remain at risk of pregnancy. Most women obtain emergency contraception from a community pharmacy (chemist), but then require an appointment with a general practitioner or at a sexual and reproductive health clinic for ongoing contraception. Getting an appointment can take time and unintended pregnancies can occur during this time.

If a pharmacist could give women a small supply of a progestogen-only pill or 'mini-pill' with their emergency contraception, together with help to get an appointment at a clinic, then this might help more women to start effective contraception.

We undertook a study in 29 pharmacies in Lothian, Tayside and London among women receiving emergency contraception. Pharmacists provided either their standard advice about contraception (control group) or the intervention. The intervention was a 3-month supply of the progestogen-only pill plus a rapid-access card, which, if presented at a sexual and reproductive health clinic, would help women get an appointment for contraception. The order in which the pharmacy provided either control or intervention was randomised. We conducted telephone interviews with the women 4 months later to find out what contraception they were using.

A total of 636 women took part in the study, 316 in the intervention group and 320 in the control group. The proportion who said that they were using an effective method of contraception was around 20% larger in the intervention group. In addition, fewer women in this group said that they had used emergency contraception again. This study shows that community pharmacy provision of a small supply of progestogen-only pills and the invitation to attend a sexual and reproductive health clinic results in a large increase in the use of effective contraception after emergency contraception. If this became routine practice then it could help prevent unintended pregnancies.



# Scientific summary

## Background

Most women who use emergency contraception in the UK access it from a community pharmacy. It is important that women start an effective ongoing method of contraception after emergency contraception if they do not want to become pregnant. However, pharmacists cannot usually provide contraception (except condoms) without a prescription. This means that to start an effective contraceptive (e.g. implant, oral contraceptive pill, etc.) women must go to a general practitioner or a sexual and reproductive health clinic. Getting an appointment is not always easy and can take time, and some women become unintentionally pregnant during this time. This trial aimed to test whether or not a community pharmacy-based intervention designed to facilitate uptake of effective contraception after emergency contraception increased the uptake of effective contraception 4 months later, compared with standard care alone. The intervention consisted of a supply of the progestogen-only pill plus the invitation of rapid access to a sexual and reproductive health clinic. The hypothesis was that the progestogen-only pill would provide temporary contraception (known as 'bridging contraception') until women could obtain their preferred method of contraception from a general practitioner or a sexual and reproductive health clinic. The rapid-access component facilitated access to a local sexual and reproductive health clinic where a full range of methods of contraception were available.

## Design

This was a pragmatic cluster randomised cohort crossover trial. Community pharmacies were cluster randomised to provide the intervention followed by control or vice versa. The Bridge-it study included a multimethod process evaluation to assess implementation, mechanisms of change and context to better understand the effectiveness of the trial.

## Setting

Twenty-nine community pharmacies in Scotland and England (Lothian, London and Tayside).

## Target population

The community pharmacist assessed the medical eligibility of women (aged  $\geq 16$  years) presenting for emergency contraception and provided this (levonorgestrel) in accordance with normal practice.

## Health technologies being assessed

The intervention consisted of provision of a 3-month supply of the progestogen-only pill (75 µg of desogestrel provided by pharmacists using a patient group direction) to be started the day after emergency contraception, together with a rapid-access card, which, on presentation at the local sexual and reproductive health clinic, helped women to be seen as a drop-in patient for advice and the provision of ongoing contraception, including long-acting reversible methods (i.e. implant, intrauterine and injectable). The control was standard care (which was advice about accessing ongoing contraception from a general practitioner or sexual and reproductive health clinic) with emergency contraception from the pharmacy. Standard care was characterised by a mystery shopper exercise that was undertaken in participating pharmacies before the control period of the trial.



## Methods

In the intervention group, pharmacists provided women with the progestogen-only pill and instructions for its use. In addition, pharmacists advised women that on presenting the rapid-access card to the local sexual and reproductive health service they would be seen as a drop-in patient for ongoing contraception. In the control group, pharmacists advised women to go to their general practitioner or a sexual and reproductive health clinic for ongoing contraception. All women completed a questionnaire on their method of contraception at 4 months. This was completed as a telephone interview with a research nurse or, if preferred, by a self-completed web-based survey. Serious adverse events were also collected at this 4-month follow-up. The main analysis was based on the intention-to-treat principle. Baseline and follow-up data were summarised using the mean (standard deviation) or median (interquartile range), where appropriate, for continuous variables. Discrete variables were summarised with numbers and percentages. The primary outcome (i.e. the proportion of events in each cluster period) was analysed using linear regression, with cluster as a fixed effect. The main analysis was adjusted for mean age, percentage of participants who are in an ongoing sexual relationship and percentage of participants who have used effective contraception methods previously.

A process evaluation of the intervention was conducted to assess implementation, fidelity and reach. The process evaluation comprised quantitative and qualitative data collection, including review of training materials; observation of training; protocol adherence checklists, and recruitment and monitoring forms; and semistructured telephone interviews with participants ( $n = 36$ ), pharmacists ( $n = 22$ ) and sexual and reproductive health service providers ( $n = 5$ ). A standardised training observation form was used to guide observations, with data transcribed into Microsoft Word (Microsoft Corporation, Redmond, WA, USA), thematic analysis conducted and descriptive summaries written. Thirteen training sessions in Scotland were observed by the process evaluation research assistant and the study trainers completed the observation forms after each training session in London. Relevant data from the pharmacist eligibility screening logs and from the 4-month follow-up surveys were entered into statistical software package IBM SPSS Statistics V.25 (IBM Corporation, Armonk, NY, USA) and descriptive analysis was conducted. Interview data were audio-recorded, transcribed verbatim and anonymised. Data analysis was undertaken using 'framework analysis', a method with proven validity and reliability, to ensure systematic thematic analysis and to facilitate synthesis of key themes. Constant comparison was carried out to ensure that the analysis represented all perspectives and negative ('deviant') cases. All process data were analysed independently from the outcome data and were documented before the outcomes were known.

## Outcomes

The primary outcome was self-reported effective contraception use (hormonal and intrauterine) at 4 months (intervention group vs. control group). Subanalysis was use of long-acting reversible contraception in both groups. Secondary outcomes included cost-effectiveness of the intervention (to be reported later) and the proportion of women in each group having undergone an abortion within 12 months, using record linkage from participants to national registries (to be reported later). Process evaluation examined the reasons that the intervention worked or did not work to inform any future implementation.

## Results

The study took place December 2017 and June 2019 and recruited 636 women to the intervention ( $n = 316$ ) and control groups ( $n = 320$ ). There were no statistically significant differences in demographic characteristics between the groups. Four-month follow-up data were available for 198 (63%) women in the intervention group and 208 (65%) women in the control group. The proportion of participants reporting use of effective contraception was 20.1% greater (95% confidence interval 5.2% to 35.0%)

in the intervention group (58.4%, 95% confidence interval 48.6% to 68.2%) than in the control group (40.5%, 95% confidence interval 29.7% to 51.3%) (adjusted for recruitment period, treatment arm and centre;  $p = 0.011$ ). The proportion of women using effective contraception remained statistically significantly larger when adjusted for age, current sexual relationship and history of past use of effective contraception, and was robust to the missing data. Long-acting reversible contraception method use was not statistically significantly different between the intervention group (13/198, 6.6%) and the control group (23/208, 11.1%) (95% confidence interval -10.04% to 1.05%;  $p = 0.112$ ).

The mystery shopper exercise undertaken to describe 'standard care' for the control group, concerning the request for emergency contraception at a community pharmacy, showed that, although pharmacists were generally helpful, obtaining emergency contraception was not always easy, waiting times were sometimes long, consultations were short and privacy was not always guaranteed. In addition, less than half of the pharmacists in the mystery shopper exercise gave any advice about ongoing contraception.

In the process evaluation, the accessibility and convenience of the pharmacy setting was highlighted as pivotal to making effective contraception more accessible. The intervention was acceptable to pharmacists and sexual and reproductive health providers, and was seen as an important way to develop and improve access to contraception and reduce repeat emergency contraception use. Reflections of implementation indicate that fidelity of delivery was, on the whole, achieved in the pharmacy context. A range of cross-cutting challenges to implementation emerged that were specific to the community pharmacy and the sexual and reproductive health context (e.g. high workloads, understaffing, changing priorities), which had an impact on delivery. Participants' accounts highlighted that providing a bridging supply of the progestogen-only pill with emergency contraception from the pharmacy as routine practice may have a positive impact on knowledge of contraception and contraceptive practices in the short term and, potentially, in the longer term by overcoming existing barriers to access and increasing confidence in accessing contraception and managing risk. Persistent barriers to accessing and using routine effective contraception remained, including worries about side effects, concerns about the commitment required, ingrained stigma related to accessing sexual health clinics, and difficulties accessing repeat prescriptions and appointments for continued contraceptive care. Such barriers are important to consider in wider implementation of bridging as a service.

## Conclusion

Provision of a bridging supply of the progestogen-only pill with emergency contraception from a community pharmacist and the invitation to a sexual and reproductive health clinic result in a significant increase in subsequent reported use of effective contraception. This simple intervention has the potential to help prevent unintended pregnancies for women after emergency contraception. As well as being acceptable to pharmacists, sexual and reproductive health providers and participants, bridging as a practice seemed feasible in the pharmacy setting, despite existing contextual challenges. This suggests that the practice could be widely implemented and routinely embedded in community pharmacies, with some adaptations to alleviate challenges and recurrent barriers to long-term use of effective contraception to encourage greater uptake. Suggestions to increase uptake of bridging contraception in the pharmacy setting include greater advertising and promotion of the service, provision of non-judgemental and supportive contraceptive consultations, an option to book routine contraceptive consultations in pharmacies outside of emergency contraception consultations and increasing the bridging contraceptive options available.

The findings of the mystery shopper study suggest that opportunities to provide emergency contraception to women and to prevent unintended pregnancy are currently being missed in community pharmacies across the UK. Lack of resources and changing priorities in the pharmacy and sexual and reproductive health contexts highlight the need for sufficient resources and time to administer any enhanced emergency contraception service and for it to be embedded in routine practice. Use of the rapid-access invitation to

sexual and reproductive health services was limited and sexual and reproductive health services faced challenges during the time of study, with funding cuts to services (London) that may have restricted access to contraception for women. It is also possible that many women preferred to access contraception from their general practitioner and that the perceived stigma of attending a sexual and reproductive health service is still a barrier. The rapid-access invitation may be a less important component of the intervention than the supply of the progestogen-only pill and therefore community pharmacies signposting to contraceptive services may suffice.

The intervention tested in this study (i.e. a 3-month supply of the progestogen-only pill) should not be a costly one, as the progestogen-only pill is an inexpensive drug, but this will be determined by a cost-effectiveness analysis, which is under way but not yet completed.

The main limitation of this study is that the outcome was uptake of effective contraception rather than unintended pregnancies. We had originally intended to examine abortion rates in each group as a co-primary outcome, but during the study it became evident that we could not recruit sufficient numbers of participants within a realistic time frame, and so we chose to focus on the uptake of effective contraception. Use of effective contraception should prevent unintended pregnancy. Although participants gave consent to allow subsequent data linkage with abortion registries, the sample size may be too small to show any difference between the groups. Another consideration is that contraceptive use was self-reported; however, there is evidence that women's self-reporting of contraceptive method is reliable. In addition, we had expected loss to follow-up in this study to be 25%, but it was larger at 35%, although there was no difference in rates between the groups. Evaluation of the impact of the intervention would be important following any future wide-scale implementation.

### **Trial registration**

This trial is registered as ISRCTN70616901.

### **Funding**

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 27. See the NIHR Journals Library website for further project information.

# Chapter 1 Introduction

## Background

Unintended pregnancy is a major public health problem. Despite having one of the highest rates of modern contraceptive use worldwide, the UK has among the highest abortion rates in Europe.<sup>1</sup> In 2018, almost 200,000 pregnancies ended in induced abortion.<sup>2,3</sup> Unintended pregnancy also ends in childbirth. Around 10% of UK births are unintended and 25% are mistimed.<sup>4</sup> Unintended pregnancy is costly to the NHS<sup>5</sup> and distressing for women. Unintended pregnancies are over-represented in young women from deprived backgrounds. Unintended childbirth can have both socioeconomic consequences for women and their families, and mental health consequences.<sup>6</sup>

Emergency contraception (EC) prevents pregnancy in individual women following unprotected sex or contraceptive accidents (e.g. burst condom). Approval of EC from pharmacies and making it free of charge to all women in Scotland and Wales, and free to many women in England, has increased use and EC is now largely obtained from pharmacies.<sup>7</sup> However, although trials have shown that facilitating access to EC increases use of EC, these trials have failed to show an effect on unintended pregnancy rates.<sup>8</sup>

Emergency contraception [containing levonorgestrel (LNG)] is only effective if taken within 72 hours of unprotected sex. It does not prevent conceptions from subsequent sex. The risk of pregnancy is increased up to threefold among women who have further unprotected sex in the same menstrual cycle after using EC.<sup>9</sup> An effective method of contraception should therefore be started as soon as possible – known as ‘quick starting’.<sup>10</sup> However, the only contraceptives available from pharmacies without prescription are condoms, which have high failure rates.<sup>11</sup> To start an effective contraceptive (i.e. hormonal or intrauterine contraception) women must visit a general practitioner (GP) or attend a sexual and reproductive health (SRH) clinic. It may take time to get an appointment and many women may lose the motivation to seek contraception, leading to an unintended pregnancy. In addition, in some UK studies, fewer than half of pharmacists gave advice about ongoing contraception after EC.<sup>12,13</sup>

There is a lack of evidence on interventions to increase uptake of effective contraception after EC. We conducted a literature search of PubMed English-language articles from 2000 to March 2020 using search terms (((bridging) OR bridge)) AND (emergency contracept\*) and identified only two relevant articles. One was a cluster randomised trial<sup>14</sup> from Jamaica, in which women seeking EC were offered a voucher that gave them a discount on the cost of contraceptive pills. This study reported no effect of the intervention on subsequent contraceptive use. The other article<sup>15</sup> was a pilot study of 12 pharmacies in Edinburgh, with 168 women presenting for EC randomised to receive 1 month of a progestogen-only pill (POP), rapid access to a local SRH clinic or standard care. Participants were contacted by telephone 6–8 weeks later to determine which method of contraception they were using. In the POP arm, 35 out of 39 (90%) women used the pills provided and 9 out of 28 (32%) women in the rapid-access arm attended the SRH clinic. Compared with standard care, the proportion of women using effective contraception after EC was statistically significantly greater in both the POP arm (56% vs. 16%;  $p = 0.001$ ) and the rapid-access arm (52% vs. 16%;  $p = 0.027$ ). The study concluded that a 1-month supply of POP after EC or rapid access to a SRH service might increase short-term uptake of effective contraception following EC, but that a high-quality, adequately powered randomised trial was needed.

## Rationale for study

Unintended pregnancy remains a public health problem in the UK. Guidance from the Faculty of Sexual and Reproductive Healthcare of the Royal College of the Obstetricians and Gynaecologists (London, UK) stresses the need to 'quick-start' ongoing contraception after EC.<sup>10</sup> In 2014, National Institute for Health and Care Excellence guidance on contraceptive services for young people endorsed this recommendation.<sup>16</sup> In some parts of the UK, pharmacies are offering women supplies of contraceptive pills after EC use,<sup>17</sup> despite the lack of evidence that this is an effective intervention or is cost-effective. We must show that the intervention is effective before we can recommend adoption of this approach. A recent cost-effectiveness analysis of EC estimated that, in 2011, unintended pregnancies cost the NHS over £1B.<sup>5</sup> It is possible that even these costs are an underestimate of the 'real costs', as they did not include the cost of managing medical complications of pregnancy or account for the additional costs associated with teenage pregnancy. If a community pharmacy-based intervention could be designed that was effective in reducing unintended pregnancies and was shown to be cost-effective, then this would result in savings for the health systems, which could be invested elsewhere. Women who present for EC should be given the best chance to prevent an unintended pregnancy.

Long-acting reversible contraception (LARC), which includes the implant, intrauterine contraception and injectable contraception, has been shown to be the most effective reversible method of contraception for preventing pregnancy.<sup>18</sup> In recognition of the effectiveness of LARC, national initiatives in the UK to increase uptake have been encouraged.<sup>16,18</sup> Rapid referral of women using EC to SRH services capable of initiating LARC immediately (as in this study) could do much to improve LARC uptake among women at risk of unintended pregnancy.

We therefore conducted the 'Bridge-It' study: a robust trial to determine whether or not a pharmacy-based intervention designed to facilitate the uptake of effective contraception after EC increases use of effective contraceptive methods, compared with standard care alone. For the Bridge-it study, we used a composite intervention of a small 'bridging' supply of the POP and the offer of rapid access to a participating SRH clinic. This combined both temporary contraception (giving women time to arrange an appointment with their usual contraceptive provider) with facilitated access to a specialist contraceptive service (i.e. the SRH clinic) where all methods of contraception, including the most effective LARC methods, are provided.

## Chapter 2 Methods

### Study design

The Bridge-it study was a pragmatic cluster randomised cohort crossover trial of community pharmacies in three regions of the UK [London (south and central), Lothian (Edinburgh and region) and Tayside (Dundee and region)].<sup>19</sup> With this design, the order in which each community pharmacy provided intervention or control was randomised. There was an intervening period of at least 2 weeks (during which recruitment halted) before the pharmacy switched to the other recruitment phase.<sup>19</sup> The cluster design was chosen as our pilot study<sup>15</sup> findings indicated that an individual randomised trial would not recruit sufficient numbers of women. The crossover was chosen for efficiency, with each cluster acting as its own control and fewer pharmacies required. The washout period between recruitment periods minimised any contamination effect of pharmacists between recruitment periods.

Pharmacies were chosen to be a mixture of large commercial chain stores and small independent stores. Each pharmacy had to have a sufficient volume of EC dispensing (at least 30 ECs per month) to participate.

Women receiving LNG EC from a study pharmacy were considered for study participation. The LNG EC was given in the appropriate dose (1.5 mg or 3 mg) for the woman's weight.<sup>10</sup>

The intervention was a composite intervention. Women received 3 months worth of the POP (75 µg of desogestrel/day) at no cost (as is the norm in the NHS) and the offer to attend a local participating SRH service to discuss and provide ongoing effective contraception, including the most effective LARC methods (i.e. intrauterine contraceptive methods and contraceptive implants).<sup>18</sup> The three packets of POP provide women with 3 months within which they could attend a contraceptive provider for ongoing contraception. The POP has very few absolute contraindications,<sup>20</sup> making it safer for pharmacy provision than the combined oral contraceptive pill. The desogestrel POP was chosen as it is the market leader, the most effective POP (as it has high rates of ovulation inhibition) and is inexpensive (£9 for 3 months of the generic version).<sup>21</sup> Community pharmacists provided the POP using locally approved patient group directions (PGDs) (i.e. strict criteria to permit provision of specified medicines by non-prescribers).<sup>21,22</sup> Participating pharmacists were trained on the study protocol and use of the PGD for the POP, including information about medical contraindications to POP, potential drug interactions and 'missed pill' guidance. Pharmacists advised women to start the POP the day after the EC. Women in the intervention group also received a rapid-access card that on presentation to the local SRH clinic would help them to be seen as a walk-in patient to discuss contraception and obtain their preferred ongoing method. The card provided information about the location of the SRH clinic and the opening hours. The clinics (three in London, one in Lothian and two in Tayside) were located within 5 miles of the community pharmacies.

In the control group, women received standard care with the EC (i.e. usual advice about ongoing contraception). Mystery shopper visits with simulated patients<sup>12,13</sup> were conducted in the pharmacies just before recruitment started in the control group to document the content of the standard care EC consultations (see *Chapter 4*).

### Participants

Pharmacists assessed women's eligibility for the study, invited them to participate, obtained written informed consent for the study (including access to SRH clinic records and data linkage with the



national abortion registries) and provided a patient information sheet. Participants completed a baseline questionnaire that included demographic details, reproductive history and previous methods of contraception used, including ECs (see *Appendix 3*). To maximise retention in the study, participants received an online shopping voucher of £10 following recruitment.<sup>23</sup>

### Procedures

Participants in both groups of the study had a single follow-up at 4 months: either a telephone interview with a research nurse or a self-administered web-based questionnaire, according to participant preference (see *Appendices 4 and 5*). In addition to contraceptive use, women were asked about their interaction with the pharmacist and use of the rapid-access card (intervention group only). Participants reporting pregnancy also completed the London Measure of Unplanned Pregnancy, which is a validated questionnaire to measure the intendedness of the index pregnancy.<sup>24,25</sup> Serious adverse events since recruitment were also recorded.

The participating SRH clinics also searched their clinic record systems for data on if and for what reason participants in both arms of the study had used their service during the 4 months following recruitment.

### Outcomes

The primary outcome was self-reported use of effective contraception (hormonal or intrauterine) at 4 months. Secondary outcomes were incidence of abortion in the 12 months following recruitment and an economic evaluation of the intervention. Both secondary outcomes will be reported later [as per agreement with the National Institute for Health Research (NIHR)].

A multimethod process evaluation was also conducted to assess implementation, mechanisms of change and context,<sup>19</sup> and included qualitative interviews with participants, pharmacists and staff at SRH clinics. The process evaluation is reported separately in this report (see *Chapter 5*).

### Sample size

An original power calculation for the study was based on two co-primary outcomes: (1) abortion rates at 12 months and (2) use of effective contraception at 4 months. For the abortion outcome, we required > 2000 women to be randomised in at least 26 pharmacies to have 90% power at 2.5% level of significance to detect a relative reduction of around 50. During the study, it became evident that recruiting this number of women was not feasible within the available time frame and resources. The independent oversight committees [the Trial Steering Committee (TSC) and Data Monitoring Committee (DMC)] and the funder (NIHR Health Technology Assessment programme) agreed to repower the study on a single primary outcome (i.e. use of effective contraception at 4 months). To have 90% power at a 5% level of significance and to demonstrate an increase from around 30% to 45% (absolute change 15%, relative increase 50%), the study required between 626 and 737 women, depending on the intraclass correlations (within period and between periods), which were not observable within the study at the time this change was made.<sup>26</sup> The sample size calculation assumed that we would not have the 4-month primary outcome data for 25% of participants and that there would be 25 participating pharmacies. For the intraclass correlations, the within-cluster, within-period correlation was 0.032 and the between-period, within-cluster correlation was also 0.032. The observed correlation between the two outcomes in the same cluster period compared with the two outcomes from different periods in the same cluster was effectively zero (< 0.00001).

## Randomisation

The order of delivery of intervention or control for each pharmacy was generated using a computer software algorithm. This randomly allocated permuted blocks of size two, four and six, and blocking was used to ensure a balanced order. The randomisation file was prepared by the study statistician at the Centre for Healthcare Randomised Trials, University of Aberdeen (Aberdeen, UK), using SAS® 6.4 for Windows (SAS Institute Inc., Cary, NC, USA). Pharmacists were informed of the randomisation allocation by the study trial manager. The study was not blinded.

## Statistical analysis

Baseline characteristics of participants and 4-month follow-up data were summarised using mean [standard deviation (SD)] or median (interquartile range) for continuous variables. Discrete variables were summarised with numbers and percentages. The published study protocol<sup>19</sup> specified a hierarchical mixed-effects logistic regression on individual data for the analysis of reported use of effective contraception at 4 months, and this represented our analysis intentions at the time of submission of the study protocol. However, we revised this primary analysis in the final statistical analysis plan (accepted 5 November 2019, before any unblinded data had been seen) to use a linear model on the unweighted proportion (expressed as a percentage) at site level, following methodological guidance from Morgan *et al.*,<sup>27</sup> and we used the hierarchical mixed-effects logistic regression as a sensitivity-type analysis. Although the linear model on percentages at site level makes less use of the available information, it can be more robust, with fewer assumptions, and expresses the treatment effect as a percentage difference in proportion rather than as an odds ratio.

Ideally, the design would generate equal contributions in each time period and each site would contribute equal numbers. However, we knew from the aggregated accruing data on the database, returned to date, that sites were quite different in size and also returning different numbers in each period. Therefore, and guided by the Morgan *et al.*<sup>27</sup> paper, which indicated that the simple approach of modelling the percentages by site had the best properties in terms of control of type 1 error, we took the unusual decision to prefer the simpler approach to the more complex hierarchical approach. This resulted in forgoing the potential increase in power traded against the possibility of model misspecification, as the model assumptions (regarding the several decompositions of within and between cluster correlation, the influence of missing data, and the influence of very different sizes by period and site) might have been violated. We felt that the hierarchical approach could still usefully be reported as a sensitivity-type analysis and, as it happened, it does seem to support the simpler analysis of proportions, giving similar estimates, but with the expected increase in precision.

For the primary outcome, the percentage of women reporting use of effective contraception in each cluster period was analysed using linear regression, adjusting for period, treatment arm and centre, and with centre as a fixed effect.<sup>27</sup> Prespecified baseline covariates (i.e. mean age, percentage of participants currently in a sexual relationship and percentage of participants who had previously used effective contraceptive methods) were included as an additional analysis. A two-sided *p*-value < 0.05 was taken as statistically significant.

For the primary outcome, prespecified subgroup analysis for LARC use<sup>18</sup> was performed using a stricter level of statistical significance (two-sided 1% significance level) and 99% confidence intervals (CIs).

The sensitivities of treatment effect estimate to missing outcome data were undertaken using multiple imputation. The missing primary outcome (i.e. uptake of effective contraception) was imputed using all baseline characteristics as predictors, except for 'previous ectopic pregnancy' (because of small numbers). Stata® version 16 (StataCorp LP, College Station, TX, USA) was used to impute 40 data sets.



## Summary of changes to the protocol

Owing to resource and time constraints, the study was repowered on a single primary outcome (i.e. effective contraception use at 7 months). For the same reasons, the planned follow-up of participants at 12 months was removed. Abortion rates at 12 months will still be collected and these and the cost-effectiveness model will be reported separately (because of a later study end date than anticipated). A summary of changes to the protocol can be found in Box 1. The final and previous versions of the protocol can be found on the NIHR Journals Library [URL: [www.journalslibrary.nihr.ac.uk/programmes/hta/1511301/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/1511301/#/) (accessed 15 February 2021)].

## Ethics

Ethics approval was obtained from South East Scotland Research Ethics Committee in June 2017. Approvals were also obtained from NHS Research Scotland (Clydebank, UK) and Health Research Authority (London, UK).

### BOX 1 Summary of changes to protocol

#### Original submission to the Research Ethics Committee

Protocol version 1, 24 May 2017

Changes were requested to the exclusion criteria and how identifiable data would be handled. The protocol was updated to version 2, 16 June 2017.

Approved.

#### Non-substantial amendment to protocol

Protocol version 3, 16 April 2018

There was a minor clarification to the wording on page 14 of the protocol to explain the time frame for the two phases of the study:

*Each pharmacy will recruit on average 80 women to provide around 60 evaluable women at 12 months. 30 women will be recruited to the intervention arm and 30 women will receive standard care. In order for each pharmacy to recruit on average 80 women, pharmacies will recruit for approximately two months in each intervention or standard care phase; some pharmacies will recruit for a shorter or longer duration depending on the recruitment rate at the pharmacy and the size of the pharmacy. However, there will be a minimum break (wash-out period) of two weeks in between the two recruitment periods.*

Approved.

#### Substantial amendment to the protocol

In December 2018, a substantial amendment was submitted to the REC.

BOX 1 Summary of changes to protocol (*continued*)

## Protocol version 4, 12 November 2018

The primary and secondary end points were updated and the sample size was reduced to 626–737 participants. The trial team also requested a 6-month no-cost extension. The changes to the sample size and extension were reviewed and approved by both the TSC and the trial funder (i.e. NIHR Health Technology Assessment programme). The end date of the study was changed from 30 September 2019 to 31 March 2020.

## Protocol version 5, 8 January 2019

The REC reviewed this in January 2019 and requested further changes to protocol to clarify at what time GPs would be contacted.

Approved.

---

REC, Research Ethics Committee.



## Chapter 3 Results

Parts of this chapter have been reproduced from Cameron *et al.*<sup>28</sup> in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

### Recruitment and participant flow

Fifty-six pharmacies were approached to participate and 32 agreed to take part in the trial (Figure 1). Twenty-nine out of the 32 pharmacies recruited participants (14 in London, 12 in Lothian and




FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart.

## RESULTS

three in Tayside). Participants were recruited between 19 December 2017 and 26 June 2019. A total of 1252 participants were screened, of whom 762 were eligible and 636 consented and were randomised. Box 2 shows the inclusion and exclusion criteria.

Table 1 shows reasons for ineligibility and Figure 2 shows participant flow. The number of participants recruited per pharmacy ranged from 2–35 in the pharmacies' first recruitment period and from 0–38 in the second period.

### BOX 2 Inclusion and exclusion criteria

#### Inclusion criteria

Eligible for LNG EC confirmed.

Able to give informed consent to participate in and adhere to trial requirements.

Aged  $\geq 16$  years.

Willing to give contact details and be contacted at 4 months by telephone, SMS, e-mail or post.

Willing to give identifying data sufficient to allow data linkage with NHS registries.

#### Exclusion criteria

Contraindications to POPs.

Taking medication that interacts with POPs.

Already using hormonal contraception.

Requires interpreting services.

Pharmacist has concerns about non-consensual sex.

SMS, short message service.

TABLE 1 Reasons for ineligibility after screening ( $n = 490$  women)

Reason	<i>n</i> (%)
Does not require EC	93 (19.0)
Lacks capacity to give informed consent	64 (13.1)
Aged < 16 years	10 (2.0)
Unwilling to give contact details and be contacted for follow-up	264 (53.9)
Unwilling to give identifying data sufficient to allow data linkage with NHS registries	262 (53.5)
Contraindication to POPs	15 (3.1)
Medication that interacts with POPs	5 (1.0)
Already using hormonal contraception	156 (31.8)
Needs an interpreter	10 (2.0)
Pharmacist concerns about non-consensual sex	2 (0.4)
<b>Note</b> Individuals may appear in more than one category.	




FIGURE 2 Participant flow chart. *n*, number of women who returned a 4-month questionnaire; *N*, number of women recruited; *P*, number of pharmacies.

Table 2 summarises the baseline characteristics of participants by randomised group and recruitment period. The mean age of participants was 22.7 (SD 5.7) years and 22.6 (SD 5.1) years in the intervention and control groups, respectively. There were no statistically significant differences between groups.

### Four-month follow-up

Follow-up data at 4 months were available for 198 out of 315 (62.9%) women and 208 out of 318 (65.4%) women in the intervention and control groups, respectively. Follow-up rates did not differ statistically between groups nor between those recruited in the first and second recruitment periods of pharmacies. There were no substantial differences in any baseline characteristics between responders and non-responders (Table 3). No significant adverse events were reported.

TABLE 2 Characteristics of participants at recruitment

Baseline characteristic	Intervention		Control	
	Period 1 (N = 229)	Period 2 (N = 86)	Period 1 (N = 161)	Period 2 (N = 155)
Age (years), mean (SD)	23.2 (6.0)	21.4 (4.8)	22.2 (4.4)	22.9 (5.8)
Methods of contraception ever used, <i>n</i> (%)				
Combined hormonal contraception	114 (49.8)	41 (47.7)	99 (61.5)	94 (59.9)
POP	39 (17.0)	19 (22.1)	35 (21.7)	32 (20.4)
Male condom	189 (82.5)	66 (76.7)	117 (72.7)	135 (86.0)
Progestogen-only injectable	14 (6.1)	6 (7.0)	10 (6.2)	18 (11.5)
Progestogen-only implant	29 (12.7)	10 (11.6)	23 (14.3)	19 (12.1)
Cu-IUD	6 (2.6)	0	4 (2.5)	4 (2.5)
LNG-IUS	0	1 (1.2)	4 (2.5)	2 (1.3)
Withdrawal method	65 (28.4)	28 (32.6)	52 (32.3)	67 (42.7)
Other methods <sup>a</sup>	10 (4.4)	6 (7.0)	7 (4.3)	9 (5.7)
Never used any method	8 (3.5)	4 (4.7)	10 (6.2)	2 (1.3)
Past birth: yes, <i>n</i> (%)	30 (13.1)	5 (5.8)	7 (4.3)	13 (8.3)
Past termination: yes, <i>n</i> (%)	38 (16.6)	6 (7.0)	22 (13.7)	27 (17.2)
Past miscarriage: yes, <i>n</i> (%)	17 (7.4)	5 (5.8)	10 (6.2)	6 (3.8)
Current sexual relationship: yes, <i>n</i> (%)	176 (76.9)	55 (64.0)	104 (64.6)	111 (70.7)
First time ever use of EC: yes, <i>n</i> (%)	52 (22.7)	22 (25.6)	28 (17.4)	32 (20.4)

continued

## RESULTS

TABLE 2 Characteristics of participants at recruitment (continued)

Baseline characteristic	Intervention		Control	
	Period 1 (N = 229)	Period 2 (N = 86)	Period 1 (N = 161)	Period 2 (N = 155)
Number of times used EC in the last 12 months				
Mean (SD)	1.4 (1.4)	1.5 (1.5)	1.5 (1.2)	1.7 (2.0)
Median (25th, 75th centile)	1.0 (0.0, 2.0)	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)
Minimum, maximum	0.0, 8.0	0.0, 9.0	0.0, 6.0	0.0, 20.0
Ethnic background, n (%)				
White	157 (68.6)	60 (69.8)	98 (60.9)	114 (72.6)
Asian or Asian British	21 (9.2)	6 (7.0)	8 (5.0)	21 (13.4)
Black or black British	29 (12.7)	12 (14.0)	36 (22.4)	15 (9.6)
Mixed or other	19 (8.3)	6 (7.0)	17 (10.6)	6 (3.8)
Missing	3 (1.3)	2 (2.3)	2 (1.2)	1 (0.6)

Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.

a Other methods of protection included female condom, cap/diaphragm, vasectomy and natural family planning.

**Note**

Previous history of ectopic pregnancy was < 1% in all groups.

TABLE 3 Characteristics (at baseline) of responders and non-responders at follow-up

Characteristic (at baseline)	Non-responders (N = 227)	Responders (N = 406)
Age (years), mean (SD)	22.3 (5.0)	22.8 (5.7)
Methods of contraception ever used, n (%)		
Combined hormonal contraception	118 (52.0)	230 (56.7)
POP	46 (20.3)	79 (19.5)
Male condom	157 (69.2)	350 (86.2)
Progestogen-only injectable	19 (8.4)	29 (7.1)
Progestogen-only implant	29 (12.8)	52 (12.8)
Cu-IUD	3 (1.3)	11 (2.7)
LNG-IUS	2 (0.9)	5 (1.2)
Female condom	0	3 (0.7)
Cap/diaphragm	0	6 (1.5)
Vasectomy	1 (0.4)	3 (0.7)
Withdrawal method	62 (27.3)	150 (36.9)
Natural family planning	7 (3.1)	13 (3.2)
Other method	1 (0.4)	2 (0.5)
Never used any method	11 (4.8)	13 (3.2)
Past birth: yes, n (%)	16 (7.0)	39 (9.6)
Past abortion: yes, n (%)	36 (15.9)	57 (14.0)
Past miscarriage: yes, n (%)	16 (7.0)	22 (5.4)
Current sexual relationship: yes, n (%)	154 (67.8)	292 (71.9)
First time ever use of EC: yes, n (%)	44 (19.4)	90 (22.2)

TABLE 3 Characteristics (at baseline) of responders and non-responders at follow-up (continued)

Characteristic (at baseline)	Non-responders (N = 227)	Responders (N = 406)
Number of times used EC in the last 12 months		
Mean (SD)	1.5 (1.2)	1.5 (1.7)
Median (25th, 75th centile)	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)
Minimum, maximum	0.0, 6.0	0.0, 20.0
Ethnic background, n (%)		
White	134 (59.0)	295 (72.7)
Asian or Asian British	25 (11.0)	31 (7.6)
Black or black British	42 (18.5)	50 (12.3)
Mixed or other	23 (10.1)	25 (6.2)
Missing	3 (1.3)	5 (1.2)

Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.

### Primary outcome: effective contraception use at 4 months

The proportion of women using effective contraception (hormonal and intrauterine contraception) was 20.1% greater (95% CI 5.2% to 35.0%) in the intervention group (58.4%, SD 21.6) than in the control group (40.5%, SD 23.8) (adjusted for recruitment period, treatment arm and centre;  $p = 0.011$ ) (Table 4).

Use of effective contraception remained statistically significantly higher in the intervention group when adjusted for recruitment period, treatment group, study centre, age, whether or not currently in a sexual relationship and history of past use of effective contraception, and was robust to the missing data (Tables 4–6) using a multiple imputation approach under an assumption of missing at random.

### Contraceptive use and long-acting reversible contraception use at 4 months

The methods of contraception used at 4 months after EC are shown in Table 7. The most common methods used were oral contraceptive pills (POPs in the intervention group and the combined hormonal contraceptive pills in the control group). There were no sterilisations or women relying on vasectomy. Use of LARC methods (e.g. implant, intrauterine and injectable) did not differ between the intervention group (13/198, 6.6%) and control group (23/208, 11.1%) (95% CI -10.04% to 1.05%;  $p = 0.112$ ).

The most common reason given by respondents for not using effective contraception at 4 months was that they were not currently sexually active (Table 8). Significantly fewer women in the intervention group than in the control group had used EC again since recruitment [20/198 (10.1%) vs. 37/208 (17.8%)] (95% CI -15.38% to -1.48%;  $p = 0.018$ ) (see Table 8).

TABLE 4 Primary analysis for cluster-level models (outcome = percentage with effective contraception use)

Analysis	Intervention, n; mean (SD)	Control, n; mean (SD)	Estimate	95% CI	p-value
Primary outcome <sup>a</sup>	21; 58.4 (21.6)	21; 40.5 (23.8)	20.1	5.2 to 35.0	0.011
Primary outcome adjusted <sup>b</sup>	21; 58.4 (21.6)	21; 40.5 (23.8)	14.5	0.9 to 28.2	0.038

a Adjusted for recruitment period, treatment arm and centre.

b Adjusted for recruitment period, treatment arm, centre, mean age, current sexual relationship and history of effective contraception use.



TABLE 5 Sensitivity analysis for cluster-level models (outcome = percentage of participants with effective contraception use)

Sensitivity analysis <sup>a</sup>	Intervention, n; mean (SD)	Control, n; mean (SD)	Estimate	95% CI	p-value
Omit cluster with fewer than three responses	14; 60.2 (19.7)	14; 42.9 (13.8)	15.2	2.3 to 28.1	0.026
Omit cluster with > 30% individuals with missing data (excluded centre from the model)	5; 58.5 (14.4)	5; 44.1 (6.6)	14.7	1.1 to 28.2	0.040
Including percentage missing and number of responders in the model	21; 58.4 (21.6)	21; 40.5 (23.8)	15.3	-0.1 to 30.6	0.051
Including percentage missing in the model	21; 58.4 (21.6)	21; 40.5 (23.8)	15.0	0.3 to 29.7	0.046
Including number of responders in the model	21; 58.4 (21.6)	21; 40.5 (23.8)	15.0	0.6 to 29.4	0.042
Multiple imputation			15.0	-2.0 to 32.0	0.076

a All analyses were adjusted for recruitment period, treatment arm, centre, mean age, current sexual relationship and history of effective contraception use.

TABLE 6 Sensitivity analysis for hierarchical models [outcome = use of effective contraception (binary)]

Analysis <sup>a</sup>	Intervention, n/N (%)	Control, n/N (%)	OR	95% CI	p-value
Fixed effects for cluster	112/198 (56.6)	85/208 (40.9)	1.93	1.21 to 3.09	0.006

OR, odds ratio.

a Adjusted for recruitment period, treatment arm and centre.

TABLE 7 Contraceptive use at the 4-month follow-up

Variable	Intervention (N = 198), n/N (%)	Control (N = 208), n/N (%)
Methods of contraception used now <sup>a</sup>		
Combined hormonal contraception	28/198 (14.1)	47/208 (22.6)
POP	71/198 (35.9)	15/208 (7.2)
Male condom	31/198 (15.7)	63/208 (30.3)
Progestogen-only injectable	4/198 (2.0)	4/208 (1.9)
Progestogen-only implant	3/198 (1.5)	11/208 (5.3)
Cu-IUD	3/198 (1.5)	4/208 (1.9)
LNG-IUS	3/198 (1.5)	4/208 (1.9)
Other method	0	1/208 (0.5)
Not using any method	57/198 (28.8)	62/208 (29.8)
LARC <sup>b</sup>	13/198 (6.5)	23/208 (11.1)
When did they start using this method?		
Same day as EC	18/141 (12.8)	14/146 (9.6)
Day after EC	38/141 (27.0)	7/146 (4.8)
With start of period after EC	13/141 (9.2)	23/146 (15.8)
Other	48/141 (34.0)	62/146 (42.5)
Missing	24/141 (17.0)	40/146 (27.4)

TABLE 7 Contraceptive use at the 4-month follow-up (continued)

Variable	Intervention (N = 198), n/N (%)	Control (N = 208), n/N (%)
Where did they get contraception from?		
GP clinic	74/141 (52.5)	53/146 (36.3)
SRH clinic	34/141 (24.1)	35/146 (24.0)
Other	21/141 (14.9)	40/146 (27.4)
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system. a Participants could use more than one method. b LARC includes Cu-IUD, LNG-IUS, progestogen-only implant and injectable.		

TABLE 8 Reasons for non-use of effective contraception at 4 months

Reasons for not using effective contraception	Intervention (N = 57), n/N (%)	Control (N = 62), n/N (%)
Not currently sexually active	27/57 (47.4)	28/62 (45.2)
Worried about side effects with contraception	12/57 (21.1)	21/62 (33.9)
Medical reasons	1/57 (1.8)	2/62 (3.2)
Not decided on method to be used	9/57 (15.8)	11/62 (17.7)
Difficult to get appointment	8/57 (14.0)	4/62 (6.5)
Difficult to find time to get to GP or SRH clinic	6/57 (10.5)	4/62 (6.5)
Trying for baby	1/57 (1.8)	0
Other	8/57 (14.0)	5/62 (8.1)
Further use of EC: yes	20/198 (10.1)	37/208 (17.8)

A significantly larger proportion of women in the intervention group reported that the pharmacist had advised them about starting ongoing contraception (98% vs. 75.5%;  $p < 0.001$ ) (Table 9).

A total of 158 out of 198 (79.8%) respondents in the intervention group reported that they used some of the study POP that the pharmacist provided. Table 10 provides data on when women started the POP, the number of packets of POPs used and reasons for non-use or discontinuation of the POP.

TABLE 9 Provision of contraceptive advice by community pharmacist

Contraceptive advice	Intervention (N = 198), n (%)	Control (N = 208), n (%)	Effect size
Did pharmacist provide information about starting contraception?			
No	2 (1.0)	46 (22.1)	0.216 (0.156 to 0.277); $p < 0.001$
Yes	194 (98.0)	157 (75.5)	
Missing	2 (1.0)	5 (2.4)	
Did pharmacist provide information about where to get contraception?			
No	19 (9.6)	67 (32.2)	0.237 (0.159 to 0.315); $p < 0.001$
Yes	178 (89.9)	134 (64.4)	
Missing	1 (0.5)	7 (3.4)	

TABLE 10 Use of POP by the intervention group

Use of POP	Intervention (N = 198), n/N (%)
Used any of the POPs that pharmacist provided?	
Yes	158/198 (79.8)
No	35/198 (17.7)
Missing	5/198 (2.5)
If not, why? <sup>a</sup>	
Not a regular partner	8/35 (22.9)
Not requiring regular contraception	7/35 (20.0)
Worried regarding side effects	10/35 (28.6)
Did not understand how to use it	1/35 (2.9)
Preferred another contraceptive	6/35 (17.1)
Used POP in the past and it did not agree	1/35 (2.9)
Preferred to see GP for contraception	2/35 (5.7)
Other	10/35 (28.6)
When did they start POPs?	
Same day as EC	27/158 (17.1)
Day after EC	93/158 (58.9)
With start of period after EC	19/158 (12.0)
Other	16/158 (10.1)
Missing	3/158 (1.9)
Number of packets of POPs used	
Less than one	15/158 (9.5)
One	17/158 (10.8)
Less than two	13/158 (8.2)
Two	8/158 (5.1)
Less than three	10/158 (6.3)
Three	70/158 (44.3)
Still taking POP	22/158 (13.9)
Missing	3/158 (1.9)
Main reason for stopping POPs before the supply ran out	
Side effects	40/158 (25.3)
Started another method	6/158 (3.8)
Other	22/158 (13.9)
Missing	90/158 (57.0)
<sup>a</sup> Participants could tick all options that apply.	

## Rapid-access card and sexual and reproductive health clinic utilisation

At the 4-month follow-up interview, 137 out of 198 (69.2%) respondents in the intervention group could recall receiving the rapid-access card, but only 31 respondents (15.6%) reported that they attended the SRH clinic. Only two respondents used the rapid-access card within 1 month of recruitment. Four out of 31 respondents (12.9%) received a LARC method at the SRH clinic (*Table 11*).

Data obtained from the SRH clinic databases showed that similar proportions of participants in both the intervention and control groups actually attended the SRH clinics within 4 months of recruitment [52/305 (17%) intervention group vs. 43/309 (13.9%) control group, 95% CI -2.60% to 8.87%;  $p = 0.284$ ]. A total of 41 out of 95 (43.1%) attendees received contraception and the methods supplied are shown in *Table 12*. There was no statistically significant difference in LARC provision to women in each group.

A total of 75 women both attended the SRH clinic and provided data at the 4-month interview. For 34 of these women, the SRH clinic provided a contraceptive method. Thirty out of 34 (88%) women reported using the same method of contraception at 4 months as the method provided by the SRH clinic.

## Pregnancies in the 4 months since emergency contraception

Nineteen respondents (4.7%) (intervention,  $n = 9$ ; control,  $n = 10$ ) reported that they had been pregnant ( $n = 17$ ) or were currently pregnant ( $n = 2$ ). The outcome of the pregnancies that had ended were abortion in 10 women (58.8%) and miscarriage in six women (35.3%); this information was unknown for one woman (5.9%). Based on the London Measure of Unintended Pregnancy<sup>24,25</sup> scores from the questionnaire, 15 out of 19 pregnancies (78.9%) had been unintended (seven in the intervention group and eight in the control group).

TABLE 11 Uptake of rapid access to the SRH clinic

Variable	Period 1 (N = 147), n/N (%)	Period 2 (N = 51), n/N (%)
Did pharmacist provide a rapid-access card?		
Yes	105/147 (71.4)	32/51 (62.7)
No	25/147 (17.0)	5/51 (9.8)
I cannot remember	12/147 (8.2)	12/51 (23.5)
Missing	5/147 (3.4)	2/51 (3.9)
Did they attend the SRH clinic?		
Yes	25/117 (21.4)	6/44 (13.6)
No	90/117 (76.9)	35/44 (79.5)
Missing	2/117 (1.7)	3/44 (6.8)
If no, why? <sup>a</sup>		
Not requiring contraception	19/90 (21.1)	9/35 (25.7)
Preferred to see a GP for contraception	45/90 (50.0)	17/35 (48.6)
Preferred to attend another SRH clinic for contraception	5/90 (5.6)	0
Other	22/90 (24.4)	8/35 (22.9)

continued

TABLE 11 Uptake of rapid access to the SRH clinic (continued)

Variable	Period 1 (N = 147), n/N (%)	Period 2 (N = 51), n/N (%)
When did they attend the SRH clinic?		
Same day as EC	1/25 (4.0)	0
< 1 month after EC	1/25 (4.0)	0
1–2 months after EC	2/25 (8.0)	1/6 (16.7)
2–3 months after EC	12/25 (48.0)	3/6 (50.0)
3–4 months after EC	4/25 (16.0)	1/6 (16.7)
Other	4/25 (16.0)	0
Missing	1/25 (4.0)	1/6 (16.7)
Did they remember to take rapid-access card to the SRH clinic?		
Yes	14/25 (56.0)	3/6 (50.0)
No	11/25 (44.0)	2/6 (33.3)
Missing	0	1/6 (16.7)
If no rapid-access card, were they refused an appointment?		
Yes	1/11 (9.1)	0
No	10/11 (90.9)	2/2 (100.0)
How long did they wait at the SRH clinic?		
< 30 minutes	8/25 (32.0)	3/6 (50.0)
< 1 hour	7/25 (28.0)	1/6 (16.7)
1–2 hours	8/25 (32.0)	1/6 (16.7)
Other	2/25 (8.0)	0
Missing	0	1/6 (16.7)
Did the SRH clinic provide a method of contraception?		
Yes	19/25 (76.0)	5/6 (83.3)
No	6/25 (24.0)	0
Missing	0	1/6 (16.7)
Did the SRH clinic provide the participant's preferred method?		
Yes	16/25 (64.0)	5/6 (83.3)
No	8/25 (32.0)	0
Missing	1/25 (4.0)	1/6 (16.7)
If no, why? <sup>a</sup>		
Not enough staff or time	2/8 (25.0)	0
Risk of pregnancy	1/8 (12.5)	0
Other	6/8 (75.0)	0
Method of contraception received		
Progestogen-only implant	1/25 (4.0)	0
Progestogen-only injectable	0	0
Cu-IUD	1/25 (4.0)	0
LNG-IUS	2/25 (8.0)	1/6 (16.7)

TABLE 11 Uptake of rapid access to the SRH clinic (continued)

Variable	Period 1 (N = 147), n/N (%)	Period 2 (N = 51), n/N (%)
Combined hormonal contraception	3/25 (12.0)	0
POP	12/25 (48.0)	4/6 (66.7)
Male condom	2/25 (8.0)	0
Experience of the rapid access to study SRH clinic		
Smooth	16/25 (64.0)	3/6 (50.0)
Neither/nor	6/25 (24.0)	2/6 (33.3)
Problematic	1/25 (4.0)	0
Missing	2/25 (8.0)	1/6 (16.7)

Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.  
 a Participants could tick all options that apply.  
**Note**  
 LARC includes Cu-IUD, LNG-IUS, and progestogen-only implant and injectable.

TABLE 12 Data from the SRH clinic databases

Variable	Intervention (N = 305), n/N (%)	Control (N = 309), n/N (%)
Attended the SRH clinic?		
No	253/305 (83.0)	266/309 (86.1)
Yes	52/305 (17.0)	43/309 (13.9)
Method of contraception provided at this visit?		
Yes	26/52 (50.0)	15/43 (34.9)
Method provided		
Progestogen-only implant	2/26 (7.7)	3/15 (20.0)
Cu-IUD	1/26 (3.8)	4/15 (26.7)
LNG-IUS	1/26 (3.8)	3/15 (20.0)
Progestogen-only injectable	0	0
Combined hormonal contraception	3/26 (11.5)	1/15 (6.7)
POP	16/26 (61.5)	2/15 (13.3)
Male condom	3/26 (11.5)	3/15 (20.0)
Other method	1/26 (3.8)	0

Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.



## Chapter 4 Mystery shopper exercise

Parts of this chapter have been reproduced from Glasier *et al.*<sup>13</sup> in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

### Mystery shopper exercise

Pharmacists were advised that one or two mystery shopper visits would take place before the control group of the study started, but they were not told when these would occur. Visits took place between April 2018 and January 2019. Research nurses recruited female volunteers (aged  $\geq 16$  years) to be mystery shoppers and instructed them on the aims of the exercise, the scenario to be followed and the data to be collected. The members of the patient and public involvement (PPI) group for the study assisted in identifying potential mystery shoppers. The shoppers received £20 for each completed visit. They followed a scenario (a single episode of unprotected sex within 72 hours) relating to a request for EC. The scenario had been approved by the PPI group. Immediately after leaving the pharmacy, shoppers completed a data collection pro forma, recording the time of arriving and leaving the pharmacy, duration of the consultation and where the consultation about EC took place. They also noted any information provided by the pharmacist, including advice on ongoing contraception. Data from the proforma were entered into an Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) database and descriptive statistics were conducted for each question.

### Results

A total of 55 mystery shopper visits were conducted at the 30 study pharmacies participating in this part of the trial. The mean total time reported spent in the pharmacy was 12 (range 1–47) minutes. The median reported duration of the consultation with the pharmacist was 6 (range 1–18) minutes. Consultations took place in a private room with 34 women (62%) and the remaining consultations took place at the counter.

Eleven mystery shoppers (20%) were unable to get EC from the pharmacy. Seven mystery shoppers reported that they were told that no trained pharmacist was available to provide EC. Four mystery shoppers were told that EC was not in stock. Two of the latter women were aged 16 years and visited the same pharmacy on the same day and both were advised to return 90 minutes later. A further two mystery shoppers were advised that a copper intrauterine device would be more effective and were directed to a SRH clinic for insertion, but neither was offered oral EC as an interim measure. Eight mystery shoppers were told that they had to swallow the EC tablets in the pharmacy and seven mystery shoppers (in London) were told that the pharmacy could not offer free EC. Three mystery shoppers were asked to provide proof of identity and age to get free EC. *Table 13* shows the results for information provided by the pharmacist around EC or ongoing contraception.

A total of 27 out of 55 (49%) mystery shoppers received advice (oral or written) about ongoing contraception. Forty-eight of the mystery shoppers made comments about their experience. Analysis of the free-text comments showed four common themes: (1) the manner of the pharmacist, (2) being requested to take the EC on the premises, (3) pharmacy not able to provide EC and (4) concerns about privacy. Examples are shown in *Box 3*.



TABLE 13 Information provided by community pharmacist

Information provided or discussed	Yes (n)	No (n)	Not completed (n)
Reason for needing EC	43	12	
Information about accessing ongoing contraception	30	25	
Oral information on importance of ongoing contraception	27	27	1
Oral advice to conduct a pregnancy test in 3 weeks	22	32	1
Written information on importance of ongoing contraception	5	50	
Written advice to conduct a pregnancy test in 3 weeks	2	53	

## BOX 3 Free-text comments from mystery shoppers

*He did however request for me to take the pill in front of him to make sure it is for me and not someone else. He said this is required legally. I then stated that I am uncomfortable with it, apologised for any inconvenience and left the pharmacy.*

*Mystery shopper B*

*They made me wait for a while and then fill out a form, which they kept. I was then told that they only had one EC pill and they needed to give me two because the law had changed so I should go elsewhere. I don't think I spoke to a pharmacist at all, just a man who worked there?*

*Mystery shopper C*

*Initially asked at counter and the lady said to wait for the pharmacist. Had to repeat to pharmacist that I needed EC. Quite a few people around.*

*Mystery shopper D*

## Discussion

The mystery shopper exercise was undertaken to describe 'standard care' for the control group regarding the request for EC at a community pharmacy. The exercise showed that, although pharmacists were generally helpful, getting EC (for which all of the women were eligible) was not always easy (1/5 did not get EC). In addition, waiting times were sometimes long, consultations short and privacy was not always guaranteed. In a few cases, women were asked for proof of identity/age, which was not a requirement of the local PGD in place for supplying EC. In addition, fewer than half of pharmacists in the mystery shopper exercise gave any advice about ongoing contraception. These findings are similar to a previous mystery shopper study from Edinburgh, published 10 years ago.<sup>12</sup> Although the current mystery shopper exercise was conducted in only 30 UK pharmacies and may therefore not be fully representative of care across the UK, all participating pharmacists had recently undergone training for the Bridge-it study and so one might have expected that the performance of these pharmacies regarding advice around ongoing contraception would have been higher.

These findings suggest that opportunities to provide EC to women and to prevent unintended pregnancy are currently being missed in community pharmacies across the UK. Furthermore, opportunities for pharmacists to discuss ongoing contraception with women provided with EC are also being missed.

This adds to the debate of whether or not EC should be available on the general sales list (i.e. available without the need for a consultation and purchasable from a range of outlets). According to the Medicines and Healthcare products Regulatory Agency (London, UK), the general sales list is appropriate for medicines that can, with reasonable safety, be sold or supplied in ways other than by or under the supervision

of a pharmacist.<sup>29</sup> The term 'with reasonable safety' has been defined as 'where the hazard to health, the risk of misuse, or the need to take special precautions in handling is small and where wider sale would be a convenience to the purchaser' (contains public sector information licensed under the Open Government Licence v3.0. URL: <https://nationalarchives.gov.uk/doc/open-government-licence/version/3/>).<sup>29</sup>

It is now more than 20 years since EC was first approved as a pharmacy medicine in the UK.<sup>7</sup> There is abundant evidence to demonstrate that it does not present a hazard to health, nor is it widely misused, and does not need special precautions. If ECs were a general sales list medicine, then there would be more opportunities to obtain it, which would benefit women and, possibly, public health.



## Chapter 5 Process evaluation

The Bridge-it study included a multimethod process evaluation to assess implementation, mechanisms of change and context to better understand the effectiveness of the trial (see *Table 14*). This chapter will report the methods employed and key findings relating to the following:

- Implementation – was the intervention implemented as planned?
- Mechanisms of change – how did the delivered intervention produce change in and impact on contraceptive practices?
- Context – how did the local and broader context affect implementation and outcomes?

Findings are common across trial sites, unless indicated otherwise. Throughout the chapter, we highlight those findings that are pertinent to future implementation of POP provision with EC.

### Methods: data sources and analysis

We employed a range of quantitative and qualitative methods, including qualitative interviews with providers (pharmacists and SRH staff) and participants, monitoring of pharmacy selection and training observations, analysis of relevant data from the 4-month follow-up questionnaire and monitoring of contemporaneous events (e.g. relevant media coverage). Further details on each data collection method and analysis approach are provided in *Appendix 1, Table 16*. Collection of such data allowed us to assess the role of our critical assumptions, mediators of change and intermediate outcomes that could impact on the effectiveness of the intervention.

All process data were analysed independently from the outcome data and documented before the outcomes were known. The process evaluation team (SP and LMCD) discussed the progress of data collection and analysis on a regular basis, allowing any issues that were encountered to be resolved (*Table 14*).

#### *Qualitative interviews with pharmacists, sexual and reproductive health providers and participants*

Qualitative interviews were conducted with those responsible for delivering the study (i.e. pharmacists and SRH providers) and those receiving the intervention (i.e. Bridge-it Study participants). The breakdown of recruitment by site is detailed in *Figure 3*. Specific details about sampling, recruitment, topics covered and analysis for each group is detailed below.

Semistructured qualitative telephone interviews were conducted with pharmacists and SRH providers to explore the acceptability of the intervention and training received (pharmacists), the perceptions of barriers to and facilitators of implementation, and existing contextual challenges within their services (see *Appendix 2*). In total, 22 pharmacists were interviewed (12 from Lothian, three from Tayside and seven from London-based pharmacies). The aim had been to interview one pharmacist from each participating pharmacy in the study. The main pharmacies not represented ( $n = 7$ ) are based in London (south), as it had not been possible to conduct interviews before the study was discontinued. Interviews were conducted between July 2018 and July 2019, with most interviews taking place once recruitment had ended in their pharmacy.

As well as interviewing pharmacists involved in the study, we interviewed five SRH providers in three out of four participating NHS sites (two in Lothian, two in Tayside and one in London) between May and October 2019. Our original aim had been to interview three or four staff members from each service; however, recruitment was challenging, particularly because of low Bridge-it study participant attendance at SRH clinics. Interviews were conducted 4–6 months after study recruitment had ended to allow time for SRH staff to have experience of participants attending their service.

TABLE 14 The Bridge-it study process evaluation framework

Measure	Questions to be answered	Method/source
Implementation	Fidelity:	Qualitative interviews with pharmacists
	<ul style="list-style-type: none"> <li>To what extent was the intervention delivered as intended?</li> </ul>	SRH providers and participants
	Acceptability and satisfaction:	Observation of pharmacist training
	<ul style="list-style-type: none"> <li>Do providers accept the intervention and adopt their roles and responsibilities?</li> <li>Do providers understand their roles and responsibilities clearly?</li> </ul>	Monitoring and screening logs Notes from TMG and TSC meetings
Mechanisms of impact	Participation and recruitment:	
	<ul style="list-style-type: none"> <li>What were the facilitators of and barriers to recruitment and participation?</li> </ul>	
	Experiences of the intervention:	4-month intervention questionnaire
	<ul style="list-style-type: none"> <li>What were participants' experiences of the intervention?</li> <li>Did participants understand and implement the intervention as intended?</li> </ul>	Qualitative interviews with pharmacists, SRH providers and participants
Context	Impacts on contraceptive knowledge and practices:	
	<ul style="list-style-type: none"> <li>How did the delivered intervention produce change?</li> <li>In practice, did the intervention address the intermediate outcomes?</li> <li>Were the mediators of change identified as being relevant to the intervention in practice?</li> <li>What were the facilitators of and barriers to uptake of effective contraception?</li> </ul>	
	How did the local and broader context affect implementation and outcomes?	Qualitative interviews with pharmacists, SRH providers and participants
	<ul style="list-style-type: none"> <li>What was the local context of the intervention (e.g. pharmacy and SRH environment) relevant to its implementation and outcomes?</li> <li>What was the broader context in which the intervention was taking place (e.g. local/national policies that may impact implementation; media coverage of reproductive health issues)?</li> </ul>	Monitoring of contemporaneous events Notes from TMG and TSC meeting
TMG, Trial Management Group.		

Qualitative interviews were also conducted with a purposive sample of 36 intervention participants (24 participants in Lothian, nine participants in London and three participants in Tayside) to explore intervention acceptability, experiences of bridging from EC to effective contraception, facilitators of and barriers to continued uptake and the wider context of their contraceptive experiences. Unintended consequences were documented through the process evaluation, including asking participants whether or not they perceived any unintended negative outcomes resulting from participation in the trial. Research nurses asked participants for consent to be contacted by the process evaluation research assistant for a qualitative interview at the end of the 4-month follow-up questionnaire, and interviews were conducted between November 2018 and October 2019. Purposive sampling was employed to recruit a representative and diverse sample, with participants sampled by area, age, use of the study POP and attendance at a SRH clinic. The characteristics of the participants who were interviewed are shown in *Table 15*.




FIGURE 3 Process evaluation flow chart.

All provider and participant interview data were audio-recorded, transcribed verbatim and anonymised. Data management was assisted by ethnographic software (NVivo 10, QSR International, Warrington, UK). Transcription and analysis (proceeding case by case) began with the first interview and was ongoing during data collection, allowing emergent themes to be identified and explored in future interviews. Data analysis was undertaken using 'framework analysis', which is a method of proven validity and reliability in which data are coded, indexed and charted systematically, then organised using a matrix or framework.<sup>30</sup> Such a method helps to ensure systematic thematic analysis and facilitates the synthesis of key themes across the data set. Constant comparison was carried out to ensure that the analysis represents all perspectives and negative ('deviant') cases.

TABLE 15 Intervention interview participant characteristics

Characteristic	Participants (n)
Age group (years)	
18–19	9
20–24	14
25–29	5
30–37	8
Location	
Lothian	24
Tayside	3
London	9
Contraceptive use at time of interview	
POP	10
Combined pill	4
Intrauterine contraception	1
Implant	1
None	20
Contraceptive service attended <sup>a</sup>	
GP	14
SRH clinic	5
No service attended	13
Unknown	6
Previous effective contraceptive use	
Yes	22
No	13
Missing	1

<sup>a</sup> Participants could attend both the GP and SRH clinic services.

### ***Monitoring of pharmacy selection and observations of training***

To evaluate reach and recruitment, pharmacy selection was recorded using a standardised template format. Study team members responsible for recruiting pharmacies routinely recorded decision-making that contributed to pharmacy selection, including number of contacts made, responses from potential pharmacies, rationales for inclusion/exclusion and reasons for acceptance/refusal.

To shed a light on intervention fidelity and delivery, and the potential impact of contextual factors, all intervention and training materials were reviewed and observations of training sessions were conducted by the process evaluation research assistant, where feasible. A standardised training observation form was used to guide observations, with a particular focus on the way key processes of the intervention were presented to and understood by pharmacists. In total, 13 training sessions were observed by the process evaluation research assistant in Scotland. In London, the study trainers completed the observation forms after each training session. Written observational data were transcribed into Microsoft Word, thematic analysis was conducted and descriptive summaries were written.

### Monitoring of contemporaneous events

To monitor local, national and international contemporaneous events that could have an impact on contraceptive use and behaviour over the course of the study, high-coverage media stories relating to contraception were monitored and recorded over the study period (i.e. July 2017–December 2019). Weekly Google Alerts (Google Inc., Mountain View, CA, USA) were set up using relevant search terms (e.g. 'contraception' and 'morning-after pill') and key information was recorded in a Microsoft Excel workbook (e.g. date of publication, news source, headline and topic focus). Relevance was assessed primarily through the scale of coverage and source of publication. Articles were included if they were published by a mainstream media source, such as widely read print/online titles (e.g. the *Daily Mail*, the *Guardian* and the *Metro*), popular magazines (e.g. *Time* and *Cosmopolitan*), popular social media news sources (e.g. *HuffPost*, *LADbible* and *BuzzFeed*) and other relevant and widely used internet sources (e.g. BBC news website, Google News and Ofcom). Over the period of the study, 736 articles were identified from mainstream media sources in the UK and were organised into key topic areas (e.g. negative focus, personal stories, emerging contraceptive methods, accessibility of contraception, contraceptive behaviour trends and general informative pieces). Descriptive summaries of key topics identified and scale of coverage were created in Microsoft Word.

### Quantitative data collected as part of the main study

Data from the pharmacist eligibility screening logs ( $n = 599$ ) and relevant data from the 4-month follow-up surveys ( $n = 406$ ) were drawn on as part of the process evaluation to shed a further light on acceptability, fidelity of implementation, barriers to participation and the uptake of routine contraception. As part of the study, pharmacists were asked to screen all of those attending for EC and to fill out a standardised screening form detailing reasons for ineligibility. Relevant data collected from the 4-month follow-up survey included participation in the intervention (e.g. if the woman used EC/POP, accessed a SRH service, started effective contraception, and if not then why not), delivery of key mechanisms by pharmacists and SRH providers (e.g. information provided on where to access further contraception, rapid-access card received and length of time at SRH service) and changes in circumstances that could influence contraceptive use (e.g. change of partner or pregnancy). Data were entered into statistical software package IBM SPSS Statistics and descriptive analysis conducted.

### Researcher field notes and meeting minutes

Throughout the study, researcher field notes and reflections were documented, and meeting minutes were analysed to record factors that may have influenced the consistency or quality of data, and contextual factors that may have had an impact on implementation.

## Synthesis of multiple data sources

After independent analysis of each data strand was completed, the findings from the multisource process evaluation were integrated to shed a light on implementation, mechanisms of change and the role of contextual factors on implementation and outcomes. To achieve this, key findings from each stage of data collection were synthesised in an analytical integration table. The table was organised to allow consideration of findings from each stage, with each strand being positioned in a single matrix for each PE component (e.g. implementation, mechanisms and context) (see *Appendix 1*). This method facilitated the systematic synthesis of the process data, drawing out synergistic interpretations to reveal a broader holistic perspective on how the intervention worked in practice.

## Implementation

### Pharmacist and sexual and reproductive health provider acceptability of the intervention

The majority of pharmacists and SRH providers were very positive about the premise of the intervention and the role of pharmacy in developing and improving contraceptive services.



Bridging in community pharmacies was seen as an important way to improve access to contraception and to reduce repeat EC use and unwanted pregnancies:

*... it shows that people are taking the issue of unwanted pregnancy seriously and they're trying to improve, you know, the accessibility of services to women ... and the choice that's available to them.*

*Pharmacist 18, Lothian*

As well as the pharmacy setting being viewed favourably, the EC consultation was seen as a particularly suitable and opportune time to offer access to routine contraception:

*I also think it's quite an opportune time when somebody comes in for emergency contraception, to pick up on, you know, sort of routine contraception. You know, the fact that they need emergency contraception, obviously something has gone wrong, so it's a good time to be able to kind of go, well actually, have you had a think about this, or how can you deal with this kind of thing?*

*SRH worker 1, Lothian*

It was suggested that approaching women in this way could break down some barriers (e.g. lack of time, difficulties accessing contraceptive appointments and avoidance) to accessing routine contraception at critical times.

### Acceptability of taking part in a research study

Figure 4 shows the pharmacist support and training that was provided for delivering the Bridge-it study. During training sessions, the majority of pharmacists seemed enthusiastic and motivated to take part in the study and often reflected on this in interviews, expressing a desire to take part in more research:

*I'm kind of like, I'd love to be involved in more things so I'm always welcome ... you know, I'm welcome to do more kind of projects like this.*

*Pharmacist 20, London*




FIGURE 4 A flow chart of pharmacist training and support for delivering the Bridge-it study.

In particular, pharmacists who had been involved in the earlier pilot study<sup>15</sup> or who had previous experience of pharmacy-based interventions were particularly enthused and seemed to be more accepting of the pharmacist role in the study, potentially because of familiarity with the kinds of processes and documentation required for trials. It is important to note that pharmacists who were particularly enthusiastic about the benefits of bridging through community pharmacies for patients, and about taking part in the study, were those who tended to recruit the most participants, perhaps highlighting the importance of 'buy-in' to the premise of the intervention.

Although most pharmacists reflected positively on the premise of the intervention and on taking part in research to expand contraceptive services, some concerns were raised during training. Pharmacists' concerns typically focused on worries relating to managing the additional time and workload pressures of taking part in a research study (rather than of delivering POP per se), scepticism that additional time would be set aside to accommodate this, and concerns about how the study would fit with existing practices and changing guidelines relating to EC. These concerns are detailed in *The impact of context on the Bridge-it study implementation and outcomes* and focus on facilitators of and barriers to delivery and implementation in practice.

## Pharmacist and sexual and reproductive health provider awareness of the study and preparedness to deliver

### *Pharmacists' perceptions of and satisfaction with training*

Observation of training demonstrated fidelity across sites, with sessions typically delivered as per the training guidance, covering all components and being consistent in content. Adaptations to training typically related to the time spent on particular components, fuelled by contextual factors such as lack of time. The majority of pharmacists were positive about the training received for the Bridge-it study and described the study as 'informative', 'concise', 'well-designed' and 'convenient'. Pharmacists typically described being satisfied with the training staff:

*... it was good, they were very clear, lovely manner the ladies had, so you didn't feel daft asking a number of questions ...*

*Pharmacist 8, Tayside*

The venue, composition and timing of training also seemed to be acceptable to the majority of pharmacists, with different options available, small-group learning-facilitating dialogue and well-timed training encouraging confidence:

*I think it was good. It wasn't a particularly large group of us doing it. I think there were about sort of 8–10 so we were able to ask questions and chat and things which was quite good .*

*Pharmacist 11, London*

*I think it worked really well, I could start it straight away and it would be fresh in my mind because the training was a week before they would launch it, so it was good.*

*Pharmacist 2, Lothian*

Pharmacists were also generally satisfied with the content of training and the study resources provided:

*... the training was pretty good, pretty informative. And I think the material provided ... stuff that they provided for reading was pretty informative as well.*

*Pharmacist 18, Lothian*

The majority of pharmacists that were interviewed indicated that the training provided prepared them to deliver the intervention as planned, but acknowledged that time and practice were necessary to be fully prepared:

*Obviously just with any of the new services it does take you just a . . . to get into a rhythm of like filling in all the paperwork and things like that.*

*Pharmacist 6, Lothian*

However, some ways in which the training could have been improved to bolster preparedness were highlighted, including through drawing on pharmacists' expertise in designing the training, increasing practice-based and role-play learning, and providing formalised refresher training between phases.

### **Awareness in sexual and reproductive health centres**

Sexual and reproductive health providers were made aware of the study through management in their services. SRH providers interviewed described a lack of familiarity with their role in the study and a general lack of awareness of the study in their service:

*I'm aware of a lot of studies but I wasn't really aware of this one too much. I never saw any of the signs. You know? I never saw anything.*

*SRH provider 5, London*

Most SRH providers indicated awareness of the study waning over time and stressed the need for reminders and easy and accessible study information to be available for all staff (including front-line reception staff).

### **Fidelity of intervention delivery**

#### **Experiences of delivery in participating pharmacies**

Pharmacists' descriptions of delivery and women's accounts of their experiences in participating pharmacies suggest that fidelity of delivery was, on the whole, achieved. Although pharmacists' descriptions of the recruitment process suggested adherence to the training protocol, there was some evidence of fatigue with research procedures, with failure to complete screening paperwork or enter data into the database relatively common across sites. Therefore, the added burden of the research context was apparent, typically extending EC consultations by approximately 15–20 minutes:

*It's a time-consuming process. So sometimes you need to manage your time really, really well and be very tight with time to fit it all in.*

*Pharmacist 1, Lothian*

Research nurses from all sites reported having to spend a substantial amount of effort on the ground to encourage pharmacists to recruit and to assist with paperwork and database entry. Such experiences suggest the need for a more streamlined process with less paperwork and repetition, and the need for a high level of in-person support during implementation. However, the nurses noted that most of this related to taking part in a research study rather than the provision of POP as a bridging method itself. The impact of the pharmacy context on implementation is described in more detail in *The impact of context on the Bridge-it study implementation and outcomes*.

Women typically discussed positive and informative experiences in participating pharmacies:

*. . . the lady who gave me all the advice on it, she was really, really thorough at explaining everything. She helped me out with the forms as well.*

*Participant 15, London*

Data from the 4-month follow-up survey demonstrated that 90% ( $n = 178$ ) of intervention participants recalled being given information about accessing further contraception during the EC consultation,

in contrast to 64% ( $n = 134$ ) of control participants. Most of the participants interviewed recalled being advised to access further contraception through either the participating SRH clinic (with rapid-access card) or their GP, typified here by participant 1, Lothian:

*... so he said that I could either go into the clinic, and he gave me one of the ticket things [rapid-access card] to hand them [...] and he also said that if I told my GP about the study and what pill it was, they'd be able to give it to me as well.*

Therefore, participants' accounts highlighted that information around further access to contraception was predominantly accurate, consistent and clear, and may have contributed to many going on to successfully access further contraception. It is important to note that most women accessed further contraception through their GP (74/141) rather than a SRH clinic (21/141), and there was no difference in the proportion of women in either the intervention group or the control group who accessed the SRH service.

Although the majority of participants described being satisfied with the information provided in the pharmacy context, some inconsistencies in information provision emerged. Some indicated that they would have benefited from more in-depth information about the study and process involved:

*I wouldn't say from the initial chat with the pharmacist that I got a totally clear picture.*

*Participant 12, Lothian*

It was not uncommon for participants to think that the aim of the study was to test out a new contraceptive pill, rather than about increasing access to further routine contraception:

*It would be because you're testing out a new drug to give out at pharmacies and GPs [...] and there was loads of girls getting asked to be part of the project to do statistics and see how it was affecting certain people.*

*Participant 10, Lothian*

This framing of the intervention and lack of understanding about the aim may have had an impact on decision-making around accessing further contraception and motivations to do so. Around one-quarter of intervention participants ( $n = 54$ ) could not recall being given a rapid-access card, typified by participant 35:

*Interviewer: Do you remember if you were given a study card?*

*Participant 35, London: No, I don't have a study card.*

*Interviewer: Were you told where to go if you had any issues with the contraception or if you wanted to get more?*

*Participant 35: Yes, he said that I could go there [pharmacy] and get my card and then obviously keep getting the pill but he wasn't there when I last went so ...*

Such accounts highlight that there were some inconsistencies in information provided to participants in participating pharmacies, which resulted in confusion and, in some cases, trouble accessing further contraception.

### Experiences within participating sexual and reproductive health clinics

As already highlighted, the SRH providers interviewed described a general lack of awareness of the study in their services, and few SRH providers interviewed described encountering Bridge-it study participants. In contrast to participants' reflections on experiences in participating pharmacies, those

who attended participating SRH clinics as part of the rapid-access component of the intervention reported less positive experiences, with a general lack of awareness among SRH staff encountered:

*I think I spoke to someone who didn't know what I was talking about, because when I went over and was like, can I have these ... I was like, I'm with the study, can I please get some more contraceptive? And I don't think she really knew, she was like, oh make an appointment with your GP.*

*Participant 5, Lothian*

Such an experience was not uncommon, with four out of the five interviewed participants who attended their local SRH centre reporting difficulties accessing an appointment for further routine contraception in this way. Two participants were unable to access rapid appointments because the services were too busy. Although one participant overcame the time-related barriers and returned on another day, another participant was asked to wait for 2–3 hours and was unable to, and thus failed to access further contraception:

*So waiting for 2 hours and being a working individual where clinics aren't open 24 hours either, I just think, you know, some things you just have to bite your tongue with. So to cut a long story short, I'm pregnant.*

*Participant 23, London*

### Barriers to recruitment

During the Bridge-it study period, recruitment was slow and initial recruitment targets were not met, both for recruiting pharmacies and participants to take part in the study. This section describes the challenges of recruiting pharmacies and explore barriers to participation in the study that may have implications for wider implementation of bridging as a service in pharmacies.

Branches of large chain pharmacies and smaller independent pharmacies were approached to take part in the study because of their proximity to the participating SRH services, large footfall and high EC dispensing rates. Initially, it was decided to approach only those pharmacies with a dispensing rate of > 30 ECs per month, which ruled out many of the smaller independent pharmacies that appeared to be easier to set up. However, because of delays with setting up some of the larger chain pharmacies, the pharmacy recruitment strategy was adapted (September 2017) to allow consideration of pharmacies with lower EC dispensing rates. In total, 21 pharmacies that were initially approached were excluded or refused to take part. Barriers to pharmacy selection and recruitment included low EC distribution, charging for EC, already being commissioned to give out oral contraception after EC, lack of interest/enthusiasm and pharmacy environment/workload (e.g. too busy, understaffed and other disruptions).

### Barriers to participation

Analysis of screening log data and pharmacist accounts in interviews indicated a variety of barriers to participation. In screening logs, pharmacists most commonly recorded unwillingness to give contact details for follow-up ( $n = 264$ ) or data linkage ( $n = 262$ ); in qualitative interviews, pharmacists expanded on these research-related barriers to participation, highlighting the time-consuming nature of paperwork and worries relating to confidentiality of data:

*... lots of them were concerned about confidentiality, they were scared that I could just share the data with the GP.*

*Pharmacist 3, Lothian*

Uncertainty around bridging as a new practice was also highlighted as a barrier to participation:

*I mean, a lot of people were a little bit ... they weren't too sure about it I suppose, but they're usually going to their doctor, so there was maybe issues there that they were just a little bit uncertain about the process of getting this through the pharmacy.*

*Pharmacist 5, Lothian*

It seemed that the unfamiliar nature of this practice acted as a deterrent to some. Some thought that these particular barriers to participation would be overcome if bridging became an established pharmacy service, with less paperwork and greater advertising and awareness of the service:

*I mean, if it was more widely known and became a more accepted pharmacy service, you would see more people.*

*Pharmacist 5, Lothian*

Pharmacists talked about greater awareness resulting in more people participating, having time to decide whether or not to participate and visiting pharmacies specifically for longer-term contraception.

As well as research-related barriers, pharmacists drew attention to some barriers to participation that may impact on uptake if bridging were widely implemented as a service in this format, which therefore require consideration. Narratives of resistance to take POP specifically or hormonal contraception generally were commonly raised by pharmacists as a barrier to participation:

*Interviewer: Do you think there's anything that prevented people from participating?*

*Pharmacist 12, Lothian: Erm, well I'd say, the choice of it only being one pill, would definitely have been one. A lot of people didn't like the fact that it was the progestogen-only one.*

As well as a lack of choice of contraceptive bridging options available, pharmacists commonly described lack of time and a sense of rush as being common to EC consultations and a barrier to further discussion:

*... the main problem is people are in a rush every time they come in to get the morning after pill.*

*Pharmacist 15, London*

Pharmacists highlighted that this sense of rush often appeared to be due to busy schedules and limited time, as well as, at times, embarrassment or a desire to move on from the event:

*I expect, embarrassment, that they just wanted to come in and out, you know, we are talking about something that people feel embarrassed about, they just want to come in, swallow the tablet, get out, forget the whole thing ever happened.*

*Pharmacist 8, Tayside*

Some pharmacists also indicated that potential participants may have been deterred by lack of time to consider participation, particularly as decision-making around contraception often requires thoughtful consideration. Therefore, the immediate need to make a decision, combined with embarrassment, lack of time and lack of choice, may have acted as barriers to participation in the study and could have an impact on uptake if bridging were widely implemented as a service. Suggestions to alleviate such barriers in wider implementation include provision of non-judgemental and supportive consultations, flexibility regarding accessing routine contraceptive services (e.g. option to book appointment) and increasing the number of contraception options available. In particular, the option of being able to book appointments to discuss further routine contraception with their pharmacist without the prerequisite of taking EC was favourable for many of those interviewed, making the service more feasible in the pharmacy setting and more beneficial for patients. Some of these potential solutions to increase uptake if bridging were widely implemented would be relatively straightforward to implement (e.g. a continuing professional development course on supportive consultations), whereas others would require practice or regulation changes. Box 4 provides a summary of key learning for future implementation.



## BOX 4 Key learning for future implementation 1

- The intervention was acceptable to pharmacists and SRH providers and was seen as an important way to develop and improve access to contraceptive services.
- A lack of awareness in SRH services emphasised the need for integration and regular communication with all services involved in implementation and delivery.
- Fidelity of delivery was mostly achieved and highlighted the importance of clear and consistent messaging around access to further contraception.
- Barriers to participation included research-related factors, as well as barriers relevant to wider implementation as a service (e.g. embarrassment, lack of time and choice).
- Suggestions to overcome barriers to participation include greater choice of contraceptive bridging methods, an option to book appointments in pharmacies and greater advertising of the service.

### ***Mechanisms of impact: participants' experiences of bridging and impacts on contraceptive practices***

This section will focus on participants' experiences of bridging and the impacts on contraceptive practices in the short and, potentially, long term. The aim is to shed a light on potential mechanisms of change and both facilitators of and barriers to uptake of bridging in future.

### ***Mechanisms of change: access, knowledge, confidence and self-efficacy***

#### **Overcoming barriers to accessing regular contraception**

Participants' descriptions of their experiences suggest that bridging in the pharmacy context may have a positive impact on contraceptive knowledge and practices, in both the short and, potentially, the long term, overcoming both personal barriers (e.g. avoidance, lack of time) and structural barriers (e.g. difficulties accessing appointments) to the uptake of routine contraception. It seemed that, for many of the participants, being approached in the pharmacy setting when attending for EC provided them with the 'push' they needed to prompt a change in their contraceptive practices:

*I think it was good because I probably would've taken a lot longer to figure it out and how to get it myself. And it was really convenient. It made me kind of realise that it was time to go on one and that it was something I did need to do.*

*Participant 10, Lothian*

This also highlights the EC consultation as an opportune moment to intervene, as indicated by pharmacists and SRH providers, and how offering bridging could interrupt potential repeat EC use, which is viewed as a persistent issue in some community-based pharmacies. As one participant highlighted:

*It was just a huge bonus to me having something that meant I didn't have to wait even longer, because I probably inevitably would have . . . in that gap again, probably had to go for more emergency contraception.*

*Participant 18, Lothian*

Participant accounts emphasised the importance of the pharmacy setting in overcoming existing access barriers to contraception in traditional contraceptive health-care settings (e.g. general practices, SRH clinics). Difficulties accessing routine contraception were commonly discussed in terms of finding the time to access contraceptive services and GP appointments, as well as in relation to the availability of services:

**Interviewer:** *So what do you think makes it difficult to access effective contraception, so to have a regular contraception?*

*Participant 8, London: I think, well, if you go to the GP or if you go to a [SRH] clinic, it's just the waiting time and you have to take quite a bit of your day up, to be honest. If you go via the GP, I have to book my appointment two, three weeks in advance.*

Participants in London seemed to struggle particularly, as one participant said:

*To be honest, getting an appointment in London is actually the worst thing ever.*

*Participant 35, London*

Participants highlighted the convenience and availability of pharmacies as pivotal in helping to overcome such existing barriers to accessing contraception:

*I know pharmacies are often open early or they're open late and they're open at lunch times so if I can go then and I don't have to book time out of work to go to a GP or a doctor that's like 09.00 to 17.00, then that would be great.*

*Participant 12, Lothian*

As well as helping to overcome barriers of time and difficulties in accessing appointments, some described how the pharmacy context could help to alleviate the potential embarrassment of accessing contraception in more traditional ways, with many valuing the fact that pharmacy consultations tended to take place in small private rooms and were typically discreet and non-judgemental:

*I think every pharmacy has a little room for you to go in and it's quite discreet.*

*Participant 19, Lothian*

Therefore, key mechanisms of change that are specific to the pharmacy setting were those of access and the nature of the setting, resulting in easier, convenient and potentially less embarrassing access to contraception.

In practice, pharmacists highlighted the immediate positive impact of being able to offer bridging contraception and the real need and demand for this service:

*... there are a lot of people come in and ask about getting contraception and what you can and can't supply and things, so some sort of extended service would probably fit in well.*

*Pharmacist 5, Lothian*

Specific populations, including young people and students, were mentioned as being particularly prone to experiencing such difficulties and being appreciative of the service. Owing to the existence of ingrained difficulties to accessing appointments in more traditional settings and the existing demand for a more accessible service through pharmacies, pharmacists typically were optimistic about the feasibility of changing behaviour through the study, highlighting a synergy between the intervention design and patient need.

### **Increased knowledge, confidence and self-efficacy**

As well as access being highlighted as a key mechanism of change, participants drew attention to a variety of other potential benefits related to taking part in the Bridge-it study. These included heightened awareness and knowledge of contraception and contraceptive services:

*I found out more about it [contraception]. I've got more knowledge of that type of stuff now so that's one of the positive things, I guess.*

*Participant 9, London*



Some described how this increased awareness and knowledge of contraception and available services improved their confidence in both accessing contraception and in relation to protecting themselves from risk:

*It's meant that I'm on the pill, I've got that sorted, I know that I can go to the pharmacy to get advice, I hopefully won't be needing the emergency contraception again, but I know that I can get it there if, for whatever reason, I need it. Yeah, I think, it's probably given me a bit more confidence with it as well.*

*Participant 36, Tayside*

*It has definitely forced me to make me more aware, so I've not had unprotected sex since then. So yes and obviously now I'm a lot more open to actually go ask about it and try and get on one.*

*Participant 7, Tayside*

Such accounts highlight key potential mechanisms of change in the uptake of effective contraception, with increased knowledge, confidence and self-efficacy possibly working to foster healthier practices and attitudes towards sexual health and risk.

Pharmacists also discussed that, although the Bridge-it study might not always be successful in driving uptake of hormonal contraceptives, the intervention likely prompted people to think more about their sexual health and consider longer-term contraception, as typified here:

**Interviewer:** *And what, if any, positive effects do you think the Bridge-it intervention had?*

**Pharmacist 17, Tayside:** *I think it had quite a lot, to be honest. A lot of people probably thinking more about their sexual health, thinking more about longer-term contraception. A lot of them hadn't maybe thought about starting on contraception after taking EC, so when I was explaining the importance of that, they were like, oh, you know, that's quite a good thing to do . . . Even the people that maybe turned me down I think it still had a positive impact on them because they'll go away and maybe think about it now, so I don't think it was negative in any way.*

This pharmacist also highlighted how further positive outcomes may be linking patients with local sexual health clinics, raising awareness of availability of testing and other related services.

### **Facilitators of and barriers to continued uptake of routine contraception**

It is important to explore why the intervention worked for some participants and not for others. As indicated in the main outcome findings, over half (122/198) of the intervention participants remained on effective contraception at the 4-month follow-up, with 36% (71/198) remaining on POP, 14% (28/198) on the combined hormonal contraceptive pill/patch/ring and 7% (13/198) on LARC methods. However, although many participants overcame barriers to continued uptake of effective contraception, 44% (88/198) of intervention participants were not on contraception at the 4-month follow-up.

### **Why did participants remain on effective contraception?**

Participants who remained on effective contraception typically found the process of accessing further supplies through their GP or SRH clinic straightforward, and tended to have positive or no side effects in response to taking POP:

*I don't feel that there has been any side effects, like, of like up and down moods or mood swings that some other women get on different pills, which is very positive.*

*Participant 1, Lothian*

*I really like it, so I've actually went and got some more of that now [ . . . ] afterwards I just went to the doctor and got some more because I don't know, I like it.*

*Participant 17, Lothian*

Familiarity was also highlighted as a reason for continued use of oral contraception specifically:

*At the moment I do feel happy on it and it's convenient, I'm used to taking the pill, and my friends are like, oh coil is so easy because you don't have to think about it, but I'm used to it.*

*Participant 18, Lothian*

A number of participants described considering changing to other options in the future. For example, participant 16 indicated that she would like to try something more long term, but had concerns relating to the implant insertion procedures:

*The implant I'm a bit scared of because sort of like the injection stuff, I'm not a fan of that, but I would want to because I think I've heard a lot of good stuff about it, so I'm not sure, yeah. Still debating it ...*

*Participant 16, Lothian*

Participant 16 later elaborated that she would also struggle to find the time to access an appointment to discuss other options, stating 'I'm just quite busy and I don't have the time to go and get another one really'.

Some of the participants who remained on effective contraception post study were those who had no prior experience of routine contraception. For example, participant 8 (London) described herself as a frequent user of EC and highlighted barriers to accessing appointments as the primary reason for not being on routine contraception prior to taking part in the Bridge-it study:

*It was just the convenience of booking an appointment. Sometimes I have to wait 3 weeks or so and then it all conflicts with my day-to-day life.*

*Participant 8, London*

Such experiences highlight the beneficial nature of offering bridging in accessible settings such as community pharmacies in overcoming existing barriers to accessing effective contraception. As well as the Bridge-it study having an impact on previous non-users, bridging seemed to be beneficial for some participants who had previous negative experiences on other forms of hormonal contraception. A minority of participants who had previous particularly negative experiences with other hormonal contraception also found the POP to be suitable:

*And to be fair these ... the pill that I'm taking just now has been great for me. And if that hadn't happened last year and nobody had talked to me about it, I don't know if I would have ever tried it, I would probably still be thinking that the pill is evil.*

*Participant 27, Lothian*

This participant had almost lost hope in the pill as a suitable method of contraception because of previous negative side effects from other oral contraception, but tried it after being approached to take part in the study and, at the time of interview, had been satisfactorily using POP since then. Such accounts highlight the barriers to accessing contraception, the sometimes time-consuming nature of finding the right contraceptive, the importance of individuals being supported in their contraceptive journeys and the benefits of offering bridging contraception through multiple routes, including community pharmacies.

### **Barriers to continued uptake of effective contraception**

The 4-month follow-up survey and interviews with participants shed a light on a range of barriers to continued uptake of POP or to seeking alternatives, which are important to consider for future implementation. For many, personal circumstances, such as not being sexually active, their current relationship status or being pregnant, resulted in them deciding to not be on contraception. Data from the 4-month follow-up survey indicated that almost half (28/57) of intervention respondents who were not on effective contraception cited such circumstances.

As well as personal circumstances, a range of other reasons were highlighted as barriers to continued uptake of effective contraception. At follow-up, one-quarter (40/158) of respondents from the intervention group discontinued POP before their supply had run out because of worries about side effects. Participants who were interviewed described a range of adverse side effects they attributed to taking POP, including spotting, prolonged bleeding, skin problems, poor mental health and mood changes, headaches, weight gain, lowered libido and nausea. The most common side effects mentioned were spotting and prolonged bleeding, typified by participant 12 (Lothian):

*There was blood every day and not much but enough to be annoying, if you know what I mean. So that's why I only took one packet and then I stopped because I was just like I can't . . .*

Prior to taking part in the Bridge-it study, 22 of the participants interviewed had previous experiences of being on regular or long-term contraception, and the majority of them attributed no longer being on contraception at the time of entry into the study to negative side effects. Therefore, for such participants, a barrier to regular uptake of contraception was not necessarily access related, but symptom and well-being related, and such accounts highlight the persistent difficulties faced by some women in their contraceptive journeys.

Some women described the commitment required to take the POP every day as a barrier to uptake, particularly in the context of busy lives:

*I think as well it can be annoying having to remember every day to take it unless you're in a really good routine.*  
*Participant 12, Lothian*

As well as difficulties in remembering to take the POP during the Bridge-it study, some described previous experiences of struggling to remember to take oral contraception in the past:

*I don't think it's hard to access it. I think, like the only thing I have found was just having it at the same time, like, every day.*  
*Participant 9, London*

Missed pills were a common reason for previous EC use, highlighting the recurring issue of user compliance and how this may act as a barrier to uptake of effective contraception.

Difficulties accessing GP/SRH clinic appointments or finding the time to attend such services to renew their supply or find an alternative were reported by one-quarter (14/57) of intervention participants. Some discussed not being able to continue accessing POP through the pharmacy as a barrier to getting further supplies:

*It's a bit of an annoyance having to do it especially when it's something that you've been on for ages and you have to almost go back just to get it prescribed.*  
*Participant 12, Lothian*

*And if I could just . . . because I don't want to have to book an appointment at the GP, you know . . . if I could just go to the pharmacy and get something I probably would have done it.*  
*Participant 22, Lothian*

Participants also discussed how the embarrassment and shame related to attending SRH clinics may have acted as a barrier to the rapid-access component of the study:

*I think I would rather go to the GP, but only because I feel like it is a little bit of a taboo to say I'm going to the [SRH] clinic.*  
*Participant 27, Lothian*

Therefore, consistent with these concerns, few intervention participants visited participating SRH clinics for further contraception (17%,  $n = 52$ ), with most of those accessing additional POP or alternatives doing so through their GPs. Such experiences highlight that, although bridging in the pharmacy setting was pivotal in helping many participants to overcome initial access barriers to routine contraception, the need to access further supplies/advice in more traditional contraceptive settings created barriers for some to remaining on effective contraception. Considerations for wider implementation to overcome such challenges could include greater linkage with general practices in the bridging process, as well as the feasibility of longer-term contraceptive care in the pharmacy setting.

Although bridging using POP was effective for many in the study, including non-users and previous users of hormonal contraception, it is important to recognise that it is not a comprehensive solution, as the remaining barriers highlight. Persistent barriers to uptake relating to well-being and access of routine effective contraception remain, emphasising the need for a package of solutions to ensure that all of these diverse different needs are met. Such challenges must be acknowledged to optimise future implementation, with attention paid to making the process of accessing ongoing contraception post bridging easier, the provision of a variety of contraceptive options and the need for a central focus on the importance of well-being during contraceptive consultations. Box 5 provides a summary of key learning for future implementation.

### ***The impact of context on the Bridge-it study implementation and outcomes***

It is important to consider context in implementation and the potential impact that existing contextual challenges may have on wider implementation.

#### **The pharmacy context: competing priorities and staffing issues**

Pharmacists provided insights into their specific pharmacy contexts during training and in interviews. The pharmacists highlighted potential facilitators of recruitment (e.g. long opening hours, accessibility, high rates of EC dispensing), as well as barriers to delivery of the Bridge-it study intervention (e.g. time pressures, lack of resources, competing demands). In particular, issues of time management and competing priorities seemed to be ingrained in community pharmacy working cultures, with common narratives emerging around high workloads and expanding roles:

**Interviewer:** *And what do you think are the main challenges of working in your pharmacy?*

**Pharmacist 8, Tayside:** *It is time I would say, it is the ever-increasing amount of roles that we have taken on and having the time to do them properly.*

#### **BOX 5 Key learning for future implementation 2**

- Provision of a bridging supply of POP with EC from the pharmacy had a positive impact on contraceptive practices in the short term and, potentially, in the longer term.
- Key mechanisms of change highlighted include ease of access, increased knowledge, awareness, confidence in accessing contraception and managing risk.
- Persistent barriers to accessing and regularly using routine contraception remain, including worries about side effects, the ingrained stigma of SRH services and difficulties accessing contraceptive appointments.
- This intervention may work well as part of a package of solutions to increase the uptake of effective contraception, ensuring that a diversity of different needs are met.
- Suggestions to increase uptake of effective contraception include greater linkage with general practices, consideration of longer-term contraceptive care in the pharmacy setting, a key focus on side effects and the importance of well-being in contraceptive consultations.

Many described a move towards transferring services from general practices, resulting in increasing responsibilities and pressures on pharmacist time. Such pressures were often exacerbated by a lack of resources and staffing issues:

*... it never feels like you have enough people.*

*Pharmacist 12, Lothian*

This seemed to be common across the participating pharmacies, fuelled by staff holidays, understaffing, high staff turnover and absence. Although such existing challenges at times contributed to low recruitment rates and a lack of engagement with the Bridge-it study, pharmacists were typically enthusiastic about embedding bridging into everyday pharmacy practice. However, it is evident that if bridging were widely implemented as a service, accounts of widespread contextual challenges highlight the need for additional resources because of the potentially time-intensive nature of such a service.

### **The sexual and reproductive health clinic context: funding cuts and changing service provision**

Sexual and reproductive health providers described SRH services being overwhelmed by different contextual factors, including patient needs and demand, staff availability, funding cuts and changing service provision. Similarly to pharmacy staff, SRH workers described continually trying to manage priorities to cope with staff shortages:

*I think that across the whole of the NHS, resources is a real issue. You know, if staff are off sick, we kind of struggle to cover things. You know, we're constantly trying to juggle, and constantly trying to desperately figure out if we take somebody off this clinic then maybe we could cover that clinic ...*

*SRH worker 1, Lothian*

Accounts highlighted the impact this could have on meeting patient expectations and needs, in relation to both the availability of appointments and the time provided for those appointments:

*We don't have enough time for appointments but also, we don't have enough appointments for the demand. You know? And because ... well, you know, services have been cut and staff [have] been cut and there's only so much, really, that you can give.*

*SRH worker 5, London*

As well as services being cut, SRH staff also spoke of services being reshaped to accommodate limited funding and resources. Two sites highlighted a move to triaging and from walk-in clinics to priority access clinics. An increased focus on young people's services was evident, as was a move away from provision of routine contraception to a focus on more specialised services, as indicated by SRH worker 3 (Tayside):

*Because obviously we were providing the more specialist stuff, whereas people that would be looking just for routine contraception would be encouraged to attend their GPs, rather than come to the specialist service, just because [of] the lack of capacity.*

These existing challenges and practice priorities had potential implications relating to the implementation of the Bridge-it study intervention and potential wider implementation of bridging as a service. Concerns were raised relating to SRH services having the resources to cope with rapid-access appointments, as well as the lack of fit with existing service provision and practice priorities. One SRH worker highlighted how exceptions to normal practice would be made for research studies:

*I think if they showed the card, though, and I've had that situation before, it's slightly different, if they have evidence that they participate in that study, so that would be slightly different.*

*SRH worker 2, Lothian*

Despite this, concerns were raised about the potential for Bridge-it study participants to be turned away or missed because of a lack of fit with current practice:

*And although the nurses were trying to get the information from patients if they had been involved in the Bridge-it study, if the patient didn't specifically explain that, they probably wouldn't have been able to get into the clinic that easily.*

SRH worker, Tayside

As already highlighted, this did happen in practice, demonstrating how existing contextual circumstances in the SRH context influenced implementation in practice. It is also important to consider how a lack of fit with existing service provision and lack of resources raises issues around how the study would fit in practice if it were widely implemented as a service in this format. If provision of routine contraception to all age groups is not a practice priority, it may make it difficult for bridging to become embedded in routine practice. Some suggested redesigning the study to refer women to general practices instead:

*I mean perhaps them going to a general practice setting would be more appropriate than directing them to sexual health, given the situation that sexual health is in nowadays, if you know what I mean. Because it is a bit more of a specialist service.*

SRH worker 3, Tayside

However, it was also highlighted that this would not be a simple solution because of an already overburdened general practice service.

### **Changing contraceptive guidelines and potential impact on policy**

Pharmacists raised concerns during training of how the study would fit with existing practices and changing guidelines relating to EC. Throughout the study period, a number of contraceptive guidelines were updated, influencing contraceptive practice and, consequently, the implementation of the study. In March 2018, new EC guidelines came into effect,<sup>10</sup> recommending another type of EC, ulipristal acetate (ellaOne®, HRA Pharma, Paris, France), as the first option rather than LNG. This had an impact on recruitment, as, if given ulipristal acetate, patients would not be eligible for the Bridge-it study. Some pharmacists described this new guidance as a barrier to recruitment and stopped recruiting participants:

*So because we'd had some additional training with [local SRH clinic] I would always offer people [ulipristal acetate] rather than [LNG] because some people would just say, you just have to have [LNG], but for me as a pharmacist and I guess as a woman as well, I would want to be giving the patient the most appropriate medicine ...*

Pharmacist 19, Lothian

As well as acting as a barrier to recruitment in the Bridge-it study, pharmacists highlighted how this guidance could have implications for bridging as a practice in pharmacies if widely implemented:

*I think with the push towards [ulipristal acetate] that'll, kind of, throw a spanner in the works for this idea. Yes. Because it obviously, you're not going to be able to take it straight away.*

Pharmacist 21, Tayside

Box 6 provides a summary of key learning for future implementation.

## **Process evaluation summary and key implications**

### **Summary of findings**

The intervention was acceptable to pharmacists and SRH providers, was seen as an important way to develop and improve access to contraceptive services, and a way to reduce repeat EC use.



### BOX 6 Key learning for future implementation 3

- Existing challenges in the participating pharmacy and SRH contexts (e.g. lack of resources and changing practice priorities) influenced implementation of the study in practice, with the deprioritisation of screening potential participants, fatigue with research procedures and participants being missed or turned away from SRH centres.
- Updated contraceptive guidance had an impact on recruitment into the study and has potential implications for the wider implementation of bridging in the current format.
- Suggested learning for wider implementation includes the need for sufficient resources and time to administer this service, and a need to consider changing service provision in SRH contexts.

Pharmacists were generally satisfied with the training received and reported that it prepared them for delivering the intervention; however, the apparent lack of awareness in SRH centres emphasised the need for regular communication. Reflections of implementation indicate that the fidelity of delivery was, on the whole, achieved in the pharmacy context, highlighting adherence to the protocol and the typically clear and consistent messaging around accessing further contraception. Analysis of screening log data and pharmacist accounts during interviews shed a light on a variety of barriers to participation in the study. Some specifically relate to the research context, whereas others are important to consider with regard to the wider implementation as a service.

Participants' accounts highlight that providing a bridging supply of POP with EC from the pharmacy as a practice may have a positive impact on knowledge of contraception and contraceptive practices in the short term and, potentially, in the longer term through overcoming existing barriers to access, increasing confidence in accessing contraception and managing risk. The process evaluation highlighted potential mechanisms of change in helping to overcome some well-established barriers to accessing longer-term contraception, including ease of access and increased knowledge, awareness of services, motivation, confidence and perceptions of self-efficacy. However, persistent barriers to accessing and using routine effective contraception remain, including worries about side effects, concerns about the commitment required, ingrained stigma related to accessing SRH clinics and difficulties accessing repeat prescriptions and appointments for continued contraceptive care. Such barriers are important to consider for future contraceptive trials and in relation to wider implementation of bridging as a service.

A broad range of factors influenced the implementation of the intervention in practice, including the context of participating pharmacies and SRH clinics, and broader changes to contraceptive guidelines. A range of cross-cutting challenges to implementation emerged that were specific to the community pharmacy and SRH context (e.g. high workloads, understaffing and changing priorities), which had an impact on delivery, with evidence of deprioritisation of screening and recruitment, fatigue with research procedures and participants being missed or turned away at SRH centres. Implementation was also influenced by key changes to contraceptive guidelines that had implications for pharmacy practice. It is important to understand such key contextual challenges to implementation and the potential impact on outcomes to shed a light on how these issues may be alleviated if bridging were widely implemented as a service.

## Key learning and implications

### *Why did the intervention work?*

The findings from the process evaluation support the conceptual framework underpinning the intervention that the offer of a bridging contraception during EC consultations along with signposting to SRH services would encourage and prompt uptake of ongoing effective contraception. As well as having a positive

impact on the uptake of effective contraception, the intervention potentially contributed to an impact for some participants in the longer term through increasing their knowledge of contraception, awareness of services, and confidence in accessing contraception and managing risk. The process evaluation shed a light on potential key mechanisms of change, including ease of access, increased knowledge and awareness of services, motivation and perceptions of self-efficacy. In particular, the convenience and accessibility of pharmacies seemed pivotal in overcoming some well-established barriers to contraception.

Accounts highlighted an existing demand for greater access to effective contraception through pharmacies, and the provision of POPs as a bridging method of contraception seemed to be generally accepted and welcomed by pharmacists, SRH providers and participants, highlighting a synergy between intervention design and patient need. As well as being acceptable to pharmacists, SRH providers and participants, bridging as a practice also seemed to be feasible in the pharmacy setting, despite existing contextual challenges, suggesting that the practice could be widely implemented and routinely embedded in community pharmacies (albeit with some adaptations to alleviate challenges and encourage greater uptake).

Although prompting positive change in contraceptive practices for many participants, it is important to acknowledge that barriers to accessing and remaining on effective contraception persist, including worries about side effects, ingrained stigma relating to accessing contraception (particularly in SRH services) and difficulties accessing appointments for continued contraceptive care. Such challenges require consideration in the design of future contraceptive trials and in the wider implementation of bridging contraception as a service, and emphasise the need for a package of solutions to ensure that this diverse range of different needs are met.

### *Implications for wider implementation*

The process evaluation shed a light on important implications for wider implementation of bridging as a service and these are detailed below. It is important to consider ways to address key implementation challenges and overcome persistent barriers to accessing and using effective contraception.

### **Key learning for wider implementation as a service**

- Adaptations to the intervention should be made to recognise existing contextual challenges in the pharmacy and SRH context, changing contraceptive guidelines and recurrent barriers to long-term use of effective contraception.
- Suggestions to increase uptake of bridging contraception in the pharmacy setting include greater advertising and promotion of the service, provision of non-judgemental and supportive contraceptive consultations, an option to book routine contraceptive consultations in pharmacies outside of EC consultations and increasing the bridging contraceptive options available.
- Suggestions to increase continued uptake of effective contraception include clear and consistent information provision about further contraceptive access, greater linkage with general practices, easier processes for obtaining repeat prescriptions and consideration of longer-term contraceptive care in the pharmacy setting. In addition, there should be a focus on both the side effects and the importance of well-being during contraceptive consultations.
- Existing contextual challenges in the pharmacy and SRH context, including lack of resources and changing practice priorities, highlight the need for sufficient resources and time to administer this service for it to be embedded in routine practice.





## Chapter 6 Discussion of the Bridge-it study

### Interpretation

The Bridge-it study demonstrated that this community pharmacist-delivered intervention of provision of a small bridging supply of oral contraception along with EC and the invitation to a SRH clinic resulted in a significantly larger proportion of women using effective contraception 4 months later than standard care alone. The difference in uptake of effective contraception between the groups was large. Furthermore, significantly fewer women in the intervention group than in the control group sought EC again during the study. In addition, consistent with the known safety of the POP,<sup>20</sup> no serious adverse events were reported. These findings are clinically important. Given that use of effective contraception prevents unintended pregnancies, the public health benefit of this simple and safe intervention is potentially considerable.

### *Why did the intervention work?*

The increase in use of effective contraception at 4 months (1 month after bridging supplies of POP in intervention group had run out) seemed to be largely related to continued use of the POP, with further supplies mostly obtained from the GP. There was evidence from the process evaluation that women who received and used the POP liked it and decided to continue with it. The POP has not traditionally been a common choice for contraception in the UK. It is estimated to be used by only 5.6%<sup>31</sup> of contraception users and is typically reserved for those with contraindications to combined hormonal contraception.<sup>20</sup>

### *Did advice from the pharmacist play a role?*

A larger proportion of women in the intervention group recalled that the pharmacist discussed contraception with them. The proportion receiving contraceptive advice in both groups of the study was much larger than in our mystery shopper exercise (49% of mystery shoppers received advice),<sup>13</sup> suggesting a possible effect of the study on pharmacist behaviour. It is possible, therefore, that the relative impact of the intervention compared with standard care in 'real life' might be greater than observed in our study.

It was a disappointment that the rapid access invitation to SRH services did not increase the proportion of women in the intervention group accessing the SRH services compared with the control group. The rapid access to a SRH clinic was used by fewer than one out of five women in the study and only two women (< 1%) used the rapid access within 1 month of EC. In our earlier pilot study, 32% of women used the rapid access to a SRH clinic.<sup>12</sup>

The process evaluation highlighted some of the difficulties facing SRH services during the study, including funding cuts to SRH services (London) that may have restricted access for these women. It was also suggested that many women prefer to access contraception from their GP and that the perceived stigma of attending a SRH service is still a barrier for some. We had included the rapid-access invitation in our study design to facilitate access to a specialist contraceptive service where all methods could be provided. Our earlier pilot study had suggested that this might increase access to and uptake of LARC;<sup>15</sup> however, we did not observe this in the current study, in which rates of LARC uptake were similar between groups. Although the rapid access may help some women to access effective contraception, the findings do suggest that this may be a less important component of the intervention than the supply of POP. Given the difficulties facing SRH services and some of the complexities highlighted by the process evaluation around SRH services being able to make rapid access available, community pharmacies signposting to contraceptive services may suffice.

## Generalisability and limitations

The Bridge-it study was a well-designed trial, with a sufficiently large sample size to show the expected effect with sufficient power. The primary outcome findings also remained consistent, even when adjusted for a range of factors and the missingness of data. The study was conducted at three different sites across the UK and the trends were consistent at each site. The Bridge-it study findings are also reassuringly consistent with the findings of our earlier pilot study.<sup>15</sup>

The pharmacies in the Bridge-it study included a mix of small independent pharmacies and large chain pharmacies, and so should reflect EC service provision across the UK. In addition, the women who participated in the Bridge-it study were of similar age and shared similar characteristics to EC users in previous studies in the UK.<sup>32</sup> The findings should therefore be applicable across the UK.

The intervention tested was a simple one (i.e. a 3-month supply of POP provided by PGDs). In addition, the intervention should not be costly, as POP is an inexpensive drug. However, this will be determined by our cost-effectiveness analysis.

This was a difficult study to undertake. Pharmacists are not usually familiar with undertaking research. The pharmacy is a commercial setting. Requiring pharmacists to recruit participants, provide study information and complete additional paperwork as part of a research study was an added burden to EC provision. Although cluster randomised trials are generally susceptible to bias as allocation is known to participants at consent, our pilot study informed us that a study design of individual randomisation in the community pharmacy setting would not work.<sup>15</sup> The study design meant that different groups of women participated in the two periods. This mix of factors contributed to varying recruitment rates across pharmacies and between periods, resulting in different lengths of required recruitment and not all pharmacies successfully recruiting in both periods. Although this added to the complexity of the study and its management, it produces more robust and generalisable findings.

The main limitation of this study (as for many contraceptive studies) is that the outcome was the uptake of effective contraception rather than the number of unintended pregnancies. We had originally intended to examine abortion rates in each group as a co-primary outcome, but during the course of the study it became evident that we could not recruit sufficient numbers of participants within a realistic time frame, and so we chose to focus solely on uptake of effective contraception, which required smaller sample size. Use of effective contraception should prevent unintended pregnancy; however, the association is more complex, particularly as the use of a method of contraception does not always equate to correct and consistent use.<sup>33</sup> Thousands of participants would have been required for this study to have the power to demonstrate an effect of the intervention on unintended pregnancies. Although participants gave consent to allow subsequent data linkage with abortion registries, the sample size may be too small to show any difference between the groups.

Another consideration is that contraceptive use was self-reported. However, there is some evidence that women's self-reporting of contraceptive method is reliable.<sup>34</sup> The findings from the limited validation exercise among those women who both obtained contraception from the SRH clinic and responded to follow-up showed that 88% of women were provided with the same method as they had reported. This provides some support for the reliability of self-reporting of contraception. Loss to follow-up for the study was 35%, which was larger than the 25% we expected. However, there was no differential loss to follow-up between groups and the characteristics of women with and without follow-up data were similar.

This study was undertaken with EC containing LNG, which was the most commonly used EC at that time and suitable for immediate start of oral contraception.<sup>35</sup> However, any future rollout of the intervention does not need to be limited to this EC, as it would also be possible for community pharmacists to provide bridging contraception of the POP containing ulipristal acetate (a more effective EC).<sup>36</sup> The only issue would be that women would be advised to wait 5 days after taking ulipristal acetate before starting the

POP (rather than immediately or the next day after EC containing LNG) because it has been shown that starting hormonal contraception sooner than 5 days after ulipristal acetate might potentially impair the ability of ulipristal acetate to delay ovulation and therefore render EC less effective.<sup>10,37,38</sup>

## Overall evidence

With the exception of our earlier pilot study,<sup>15</sup> to the best of our knowledge, the only published study that examined the uptake of effective contraception after EC offered women (in Jamaica) a discount on the subsequent cost of contraceptive pills and had no effect on subsequent contraceptive use.<sup>14</sup> The only other intervention that has demonstrated a large impact on the use of effective contraception was the Contraceptive CHOICE Project in the USA,<sup>39</sup> in which women requiring contraception in a range of settings were counselled about LARC and provided with their chosen method free of charge in a setting where contraception is usually not free. LARC uptake was 67% in the Contraceptive CHOICE Project cohort, compared with 3% nationally. The Bridge-it study, by comparison, assessed a simple intervention delivered by community pharmacists at EC request.

## Recommendations for research

Future research should be directed at a robust evaluation of the impact of the Bridge-it study intervention following any wide-scale implementation (to include impact on abortion rates, cost-effectiveness and on experiences of women and community pharmacists following implementation). This should be cognisant of existing contextual challenges in the pharmacy and SRH context.

The findings of the Bridge-it study are particularly relevant to the NHS during the current Covid-19 pandemic. Pharmacists are already embedded in SRH care in the UK and could provide an alternative way for women to access regular effective contraception.<sup>40</sup> As part of the NHS Long Term Plan, NHS England plans to work with the government to make greater use of community pharmacists' skills and opportunities to engage patients.<sup>41,42</sup> As part of the deal, the NHS is introducing an expanded clinical role for local pharmacists, beginning 'a revolution in patient care' that could see community pharmacy becoming the first port of call for minor illness and health advice.

Therefore, we propose that future research should also focus on the feasibility, acceptability and impact of more contraceptive services being delivered from community pharmacies. Our process evaluation has highlighted the need for sufficient resources for such services to be embedded in routine practice. In doing so, and alongside appropriate advertising and promotion of the service and an emphasis on well-being during contraceptive consultations, services could overcome persistent barriers to accessing and using effective contraception.

Future research should also consider ways to better support research in the community pharmacy setting.

## Implications for decision-makers

### *What if offering a 3-month supply of the progestogen-only pill with emergency contraception became standard practice throughout the UK?*

Emergency contraception users are a group who are at high risk of unintended pregnancy. A subsequent increase of 20% in contraceptive uptake is a large and clinically important increase. Pharmacy provision of POP is inexpensive. A 3-month supply of the desogestrel POP costs the NHS approximately £3 and the estimated cost of the pharmacist's time is around £30.<sup>21,43</sup> Provision of a bridging supply of POP with EC has received support in surveys of EC users and also from members of the Faculty of Sexual and Reproductive Healthcare.<sup>32,44</sup> In addition to increasing uptake of effective contraception, it is likely

that widely implementing bridging POP might also reduce rates of repeat EC use (as observed in the Bridge-it study), which would also generate savings (through reduced consultations for EC).

Some may be concerned that the intervention could discourage use of LARC. However, there were no significant differences between the two arms of the study in uptake of LARC after EC use. Existing evidence plus the data from interviews with participants, pharmacists and SRH clinic staff, conducted as part of the process evaluation, showed that not all women wish to use LARC<sup>45</sup> and many value the control they have with a method such as a pill, which allows them to start and stop the contraception themselves. Furthermore, mathematical modelling from the USA suggests that relatively more unintended pregnancies at population level would be prevented by efforts focused on encouraging women who are not using an effective contraceptive method to use one (e.g. POP), compared with switching those already using an effective method to a more effective LARC method.<sup>46</sup>

We chose to provide the POP as bridging contraception over the more commonly used combined oral contraceptive pill because the latter has more contraindications and health risks.<sup>20</sup> The POP used in the study (i.e. 75 µg of desogestrel/day) consistently inhibits ovulation in almost all users (in contrast to older POPs), and so is likely to be as effective as the combined oral contraceptive and is easier to use as it is taken every day without a break.

This study has enormous implications for public health policy, as it provides evidence for a simple, effective strategy that could prevent more unintended pregnancies for women.

Unintended pregnancies may end in abortion, but may also result in miscarriage or an unplanned birth. Better pregnancy planning can improve outcomes for babies and mothers.

Although this intervention has the potential to be cost-effective, this will not be known until the results of the planned health economics analysis has been completed.

In addition, we are aware of pharmacies in some settings already supplying an oral contraceptive pill along with EC, yet without any robust evidence to support this practice.<sup>17</sup> The Bridge-it study provides the robust evidence required and also the evidence to support any future wide-scale implementation.

## Chapter 7 Conclusions

Provision of a bridging supply of POP with EC from a pharmacist clinic provides temporary contraception (POP) to prevent unintended pregnancies from unprotected sex in the same cycle and subsequent cycles. The provision of a rapid-access card to a SRH clinic was designed to facilitate access to contraceptive services (SRH clinic), but we did not find evidence that this approach was effective.

The Bridge-it study showed that this intervention resulted in a significant increase in subsequent reported use of effective contraception, which has the potential to prevent unintended pregnancies for women after EC. A reduction in unintended pregnancies would also save costs for the NHS and a cost-effectiveness analysis will report on this.

Evaluation of the impact of this intervention would be important following any future wide-scale implementation.

### Impact of patient and public involvement, challenges of patient and public involvement and lessons learnt

#### *Pre-funding study design and protocol development*

We used the local PPI network at the SRH service in Lothian to help inform and improve the study design and recruitment plan. We also held small group meetings with women attending our specialist contraceptive services, teenage mothers attending toddlers groups, pregnant women in the Family Nurse Partnership programme and members of the local abortion rights group. The study name, protocol and original Health Technology Assessment programme application were reviewed and approved by the chairperson and members of the PPI group. The *Plain English summary* of the application was edited by a PPI member (a 16-year-old woman) and was improved as a result. We also used our PPI network to help address questions from the Health Technology Assessment board.

#### *Mystery shopper exercise*

We used our PPI members from the TSC and local PPI members at each site to help identify potential 'mystery shoppers' for the pharmacy visits.

#### *Trial Steering Committee and key project decisions*

Patient and public involvement members commented on the participant information sheet and consent documentation, and, in response to this, some changes were made and these documents were improved as a result. The input of the PPI members on key recruitment issues arising during the course of the study (relating to slower than expected recruitment) was highly valuable, as was their positive voice on the decision to repower the study on the primary outcome of effective contraception use at 4 months (confirmed by PPI members as an important outcome for women).

The PPI members have also approved drafts of papers and reports. The PPI network (including a 17-year-old woman) and the PPI representatives on our TSC also made suggestions to improve the *Plain English summary* in this report.

#### *Dissemination*

The PPI members will be involved in dissemination of the main study findings through their networks and social media.

The findings of the mystery shopper exercise have already been published<sup>13</sup> (online early) and a PPI member is writing a patient opinion piece to be submitted to the same journal and hopefully published alongside this.



# Acknowledgements

We wish to thank the women who participated in this study, community pharmacists at the study pharmacies who recruited women to the study, and health-care professionals at the study SRH clinics who assisted with the implementation of the study (see below). Thanks to research staff Deirdre Sally, Nicola Stewart and Maria Nunez (University College London, London, UK) for their support with implementation of the study at local sites in London, and Kristina Saunders (University of Glasgow, Glasgow, UK) for support with process evaluation. Thanks to Sarah Cameron and Lorna Aucott (senior statistician, Centre for Healthcare Randomised Trials) for support. Thanks to Katherine Lewis, Laura Flett and Judith Parker (Edinburgh Clinical Trials Unit, Edinburgh, UK) for trial management support. Thanks also to Katherine Lewis for assistance in the compilation of this report.

## List of study pharmacies

Newington Pharmacy, Edinburgh; Boots Princes Street, Edinburgh; Boots Shandwick Place, Edinburgh; Boots Earl Grey Street, Edinburgh; Boots Gyle, Edinburgh; Boots St Patrick Street, Edinburgh; Boots Multrees Walk, Edinburgh; Boots Ocean Terminal, Edinburgh; Boots Edinburgh Fort Retail Park, Edinburgh; Boots Cameron Toll, Edinburgh; Boots Craigleith, Edinburgh; Bristo Square Pharmacy, Edinburgh; Asda Pharmacy, Perth; Boots High Street, Dundee; Boots Perth Road, Dundee; Peace Pharmacy, London; Westbury Chemist, London; Baba Chemist, London; Lings Chemist, London; Streatham Day Lewis, London; Morrisons, Aylesham Centre, London; Evergreen Pharmacy, London; Greenlight Pharmacy, London; Sandylight Pharmacy, London; Greenfields (Day Lewis), London; JP Pharmacy, London; Boots Goodge Street, London; Boots Tottenham Court Road, London; and Boots Holborn, London.

## List of study sexual and reproductive health clinics

Chalmers Sexual and Reproductive Health Service, Edinburgh; Tayside Sexual and Reproductive Health Service, Ninewells Hospital, Dundee; Camberwell Sexual Health Centre, London; and The Margaret Pyke/Mortimer Market Centres or the Archway Centre, London.

## Collaborators

The Bridge-it study TSC provided oversight for this trial on behalf of the sponsor (University of Edinburgh and NHS Lothian) and the funder. The members are Peter Brocklehurst (chairperson), Birmingham Clinical Trials Unit; Lucy Michie, NHS Ayrshire and Arran; Kaye Wellings, London School of Hygiene and Tropical Medicine; Joanna Loudon, PPI member, Edinburgh; Kirsten Stuart, PPI member, Edinburgh; and Emily Whitaker, PPI member, Edinburgh.

The DMC is an independent multidisciplinary group, consisting of clinicians and statisticians. The members are Claire Anderson (chairperson), University of Nottingham; Elizabeth Allen, London School of Hygiene and Tropical Medicine; and Caroline Moreau, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. A copy of the DMC charter is held in Edinburgh Clinical Trials Unit.

The study has co-sponsorship between the University Court of the University of Edinburgh and Lothian Health Board. The sponsors' representative is the Academic and Clinical Central Office for Research and Development (ACCORD) (Edinburgh, UK).



## Contributions of authors

**Sharon T Cameron** (<https://orcid.org/0000-0002-1168-2276>) was responsible for the study design, wrote the first draft of the report, with significant input from all authors at all stages, and contributed to, read and approved the final report.

**Anna Glasier** (<https://orcid.org/0000-0002-5697-255X>) was responsible for the study design, wrote the first draft of the report, with significant input from all authors at all stages, and contributed to, read and approved the final report.

**Lisa McDaid** (<https://orcid.org/0000-0002-7711-8723>) was responsible for the study design, wrote the process evaluation component, and contributed to, read and approved the final report.

**Andrew Radley** (<https://orcid.org/0000-0003-4772-2388>) was responsible for the study design, and contributed to, read and approved the final report.

**Susan Patterson** (<https://orcid.org/0000-0003-1846-5749>) contributed to later stages of study design and analysis, wrote the process evaluation component, and contributed to, read and approved the final report.

**Paula Baraitser** (<https://orcid.org/0000-0002-3354-6494>) was responsible for the study design, and contributed to, read and approved the final report.

**Judith Stephenson** (<https://orcid.org/0000-0002-8852-0881>) was responsible for the study design, and contributed to, read and approved the final report.

**Richard Gilson** (<https://orcid.org/0000-0002-9572-193X>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Claire Battison** (<https://orcid.org/0000-0001-9549-4522>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Kathleen Cowle** contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Thenmalar Vadiveloo** (<https://orcid.org/0000-0001-5531-6289>) was responsible for the statistical analyses and contributed to data interpretation, and contributed to, read and approved the final report.

**Anne Johnstone** (<https://orcid.org/0000-0003-1886-2138>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Alessandra Morelli** (<https://orcid.org/0000-0002-9803-2136>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Beatriz Goulao** (<https://orcid.org/0000-0003-1490-7183>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Mark Forrest** (<https://orcid.org/0000-0002-2395-8823>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

**Alison McDonald** (<https://orcid.org/0000-0002-0256-2889>) contributed to later stages of study design and analysis, and contributed to, read and approved the final report.

John Norrie (<https://orcid.org/0000-0001-9823-9252>) was responsible for the study design, wrote the first draft of the report, with significant input from all authors at all stages, and contributed to, read and approved the final report.

## Publications

Cameron ST, Baraitser P, Glasier A, McDaid L, Norrie J, Radley A, *et al.* Pragmatic cluster randomised cohort cross-over trial to determine the effectiveness of bridging from emergency to regular contraception: the Bridge-It study protocol. *BMJ Open* 2019;**9**:e029978.

Cameron ST, Glasier A, McDaid L, Radley A, Baraitser P, Stephenson J, *et al.* A pragmatic cluster randomised crossover trial to determine use of effective contraception following provision of the progestogen-only pill to women presenting to community pharmacies for emergency contraception: the Bridge-it study. *Lancet* 2020;**396**:1585–94.

Glasier A, Baraitser P, McDaid L, Norrie J, Radley A, Stephenson JM, *et al.* Emergency contraception from the pharmacy 20 years on: a mystery shopper study. *BMJ Sex Reprod Health* 2021;**47**:55–60.

## Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to available anonymised data may be granted following review.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.



# References

1. Sedgh G, Singh S, Shah IH, Ahman E, Henshaw SK, Bankole A. Induced abortion: incidence and trends worldwide from 1995 to 2008. *Lancet* 2012;**379**:625–32. [https://doi.org/10.1016/S0140-6736\(11\)61786-8](https://doi.org/10.1016/S0140-6736(11)61786-8)
2. Department of Health and Social Care (DHSC). *Abortion Statistics, England and Wales*. London: DHSC; 2014.
3. Information Services Division. *Abortion Statistics*. Edinburgh: Information Services Division; 2018.
4. Wellings K, Jones KG, Mercer CH, Tanton C, Clifton S, Datta J, *et al*. The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). *Lancet* 2013;**382**:1807–16. [https://doi.org/10.1016/S0140-6736\(13\)62071-1](https://doi.org/10.1016/S0140-6736(13)62071-1)
5. Thomas CM, Cameron S. Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC. *BMJ Open* 2013;**3**:e003815. <https://doi.org/10.1136/bmjopen-2013-003815>
6. Smith Battle L, Leonard V. Inequities compounded: explaining variations in the transition to adulthood for teen mothers' offspring. *J Fam Nurs* 2012;**18**:409–31. <https://doi.org/10.1177/1074840712443871>
7. Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. *BMJ* 2005;**331**:271. <https://doi.org/10.1136/bmj.38519.440266.8F>
8. Polis CB, Schaffer K, Blanchard K, Glasier A, Harper CC, Grimes DA. Advance provision of emergency contraception for pregnancy prevention (full review). *Cochrane Database Syst Rev* 2007;**2**:CD005497. <https://doi.org/10.1002/14651858.CD005497.pub2>
9. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. *Cochrane Database Syst Rev* 2012;**8**:CD001324. <https://doi.org/10.1002/14651858.CD001324.pub4>
10. Faculty of Sexual and Reproductive Healthcare. *Emergency Contraception Guidance*. 2012. URL: [www.fsrh.org](http://www.fsrh.org) (accessed 11 January 2016).
11. Trussell J. *Contraceptive Efficacy*. 2014. URL: [www.glowm.com/section\\_view/heading/contraceptive-efficacy/item/374](http://www.glowm.com/section_view/heading/contraceptive-efficacy/item/374) (accessed 18 February 2021).
12. Glasier A, Manners R, Loudon JC, Muir A. Community pharmacists providing emergency contraception give little advice about future contraceptive use: a mystery shopper study. *Contraception* 2010;**82**:538–42. <https://doi.org/10.1016/j.contraception.2010.05.008>
13. Glasier A, Baraitser P, McDaid L, Norrie J, Radley A, Stephenson JM, *et al*. Emergency contraception from the pharmacy 20 years on: a mystery shopper study. *BMJ Sex Reprod Health* 2021;**47**:55–60. <https://doi.org/10.1136/bmj.srh-2020-200648>
14. Chin-Quee DS, Wedderburn M, Otterness C, Janowitz B, Chen-Mok M. Bridging emergency contraceptive pill users to regular contraception: results from a randomized trial in Jamaica. *Contraception* 2010;**81**:133–9. <https://doi.org/10.1016/j.contraception.2009.08.015>
15. Michie L, Cameron ST, Glasier A, Larke N, Muir A, Lorimer A. Pharmacy-based interventions for initiating effective contraception following the use of emergency contraception: a pilot study. *Contraception* 2014;**90**:447–53. <https://doi.org/10.1016/j.contraception.2014.05.004>

16. National Institute for Health and Care Excellence (NICE). *Contraceptive Services for Under 25s*. London: NICE; 2014.
17. Parsons J, Adams C, Aziz N, Holmes J, Jawad R, Whittlesea C. Evaluation of a community pharmacy delivered oral contraception service. *J Fam Plann Reprod Health Care* 2013;**39**:97–101. <https://doi.org/10.1136/jfprhc-2012-100304>
18. National Institute for Health and Care Excellence (NICE). *Long-acting Reversible Contraception*. London: NICE; 2005.
19. Cameron ST, Baraitser P, Glasier A, McDaid L, Norrie J, Radley A, et al. Pragmatic cluster randomised cohort cross-over trial to determine the effectiveness of bridging from emergency to regular contraception: the Bridge-It study protocol. *BMJ Open* 2019;**9**:e029978. <https://doi.org/10.1136/bmjopen-2019-029978>
20. Faculty of Sexual and Reproductive Healthcare. *UK Medical Eligibility Criteria for Contraceptive Use*. London: Faculty of Sexual and Reproductive Healthcare; 2016.
21. Joint Formulary Committee. *British National Formulary (online)*. London: BMJ Group and Pharmaceutical Press. URL: [www.medicinescomplete.com](http://www.medicinescomplete.com) (accessed 9 March 2021).
22. Medicines and Healthcare products Regulatory Authority (MHRA). *Patient Group Directions – Who Can Use Them*. London: MHRA; 2017.
23. Brueton VC, Tierney J, Stenning S, Harding S, Meredith S, Nazareth I, et al. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev* 2013;**12**:MR000032. <https://doi.org/10.1002/14651858.MR000032.pub2>
24. Cameron ST, Glasier A. Identifying women in need of further discussion about the decision to have an abortion and eventual outcome. *Contraception* 2013;**88**:128–32. <https://doi.org/10.1016/j.contraception.2012.10.032>
25. Hall JA, Stephenson J, Barrett G. On the stability of reported pregnancy intentions from pregnancy to 1 year postnatally: impact of choice of measure, timing of assessment, women's characteristics and outcome of pregnancy. *Maternal Child Health J* 2019;**23**:1177–86. <https://doi.org/10.1007/s10995-019-02748-x>
26. Arnup SJ, McKenzie JE, Hemming K, Pilcher D, Forbes AB. Understanding the cluster randomised crossover design: a graphical illustration of the components of variation and a sample size tutorial. *Trials* 2017;**18**:381. <https://doi.org/10.1186/s13063-017-2113-2>
27. Morgan KE, Forbes AB, Keogh RH, Jairath V, Kahan BC. Choosing appropriate analysis methods for cluster randomised cross-over trials with a binary outcome. *Stat Med* 2017;**36**:318–33. <https://doi.org/10.1002/sim.7137>
28. Cameron ST, Glasier A, McDaid L, Radley A, Baraitser P, Stephenson J, et al. A pragmatic cluster randomised crossover trial to determine use of effective contraception following provision of the progestogen-only pill to women presenting to community pharmacies for emergency contraception: the Bridge-it study. *Lancet* 2020;**396**:1585–94. [https://doi.org/10.1016/S0140-6736\(20\)31785-2](https://doi.org/10.1016/S0140-6736(20)31785-2)
29. Medicines and Healthcare products Regulatory Agency (MHRA). *Guidance. Medicines: Reclassify Your Product*. London: MHRA; 2014.
30. Ritchie J, Lewis J. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London: SAGE Publications Ltd; 2003.

31. Cea-Soriano L, García Rodríguez LA, Machlitt A, Wallander MA. Use of prescription contraceptive methods in the UK general population: a primary care study. *BJOG* 2014;**121**:53–60. <https://doi.org/10.1111/1471-0528.12465>
32. Michie L, Cameron ST, Glasier A, Greed E. Contraceptive use among women presenting to pharmacies for emergency contraception: an opportunity for intervention. *J Fam Plann Reprod Health Care* 2014;**40**:190–5. <https://doi.org/10.1136/jfprhc-2013-100730>
33. Wellings K, Brima N, Sadler K, Copas AJ, McDaid L, Mercer CH, *et al.* Stopping and switching contraceptive methods: findings from Contessa, a prospective longitudinal study of women of reproductive age in England. *Contraception* 2015;**91**:57–66. <https://doi.org/10.1016/j.contraception.2014.09.008>
34. Smith C, Edwards P, Free C. Assessing the validity and reliability of self-report data on contraception use in the MOBILE Technology for Improved Family Planning (MOTIF) randomised controlled trial. *Reprod Health* 2018;**15**:50. <https://doi.org/10.1186/s12978-018-0494-7>
35. Baird AS. Use of ulipristal acetate, levonorgestrel and the copper-intrauterine device for emergency contraception following the introduction of new FSRH guidelines. *J Fam Plann Reprod Health Care* 2013;**39**:264–9. <https://doi.org/10.1136/jfprhc-2012-100467>
36. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, *et al.* Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet* 2010;**375**:555–62. [https://doi.org/10.1016/S0140-6736\(10\)60101-8](https://doi.org/10.1016/S0140-6736(10)60101-8)
37. Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of ulipristal acetate when ‘quickstarting’ a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. *Hum Reprod* 2015;**30**:1566–72. <https://doi.org/10.1093/humrep/dev115>
38. Brache V, Cochon L, Duijkers IJ, Levy DP, Kapp N, Monteil C, *et al.* A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Hum Reprod* 2015;**30**:2785–93. <https://doi.org/10.1093/humrep/dev241>
39. Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. *Obstet Gynecol* 2012;**120**:1291–7. <https://doi.org/10.1097/AOG.0b013e318273eb56>
40. Heller R, Johnstone A, Cameron ST. The feasibility of contraceptive injections at the community pharmacy. *Eur J Contracept Reprod Health Care* 2017;**22**:327–33. <https://doi.org/10.1080/13625187.2017.1357808>
41. Iacobucci G. Pharmacists could be allowed to prescribe high dose statins under NHS plan. *BMJ* 2019;**366**:i5447. <https://doi.org/10.1136/bmj.i5447>
42. NHS England. *A Summary of the Community Pharmacy Contractual Framework for 2019/20 to 2023/24: Supporting Delivery for the NHS Long Term Plan*. London: NHS England; 2019.
43. NHS National Services Scotland. *Emergency Hormonal Contraception (EHC)*. URL: <https://nhs.uk/services/practitioner/pharmacy/pharmacy-services/public-health-services/emergency-hormonal-contraception-ehc/> (accessed 3 June 2020).
44. Boog K, Chen ZE, Cameron S. Sexual and reproductive healthcare providers’ opinions on expansion of pharmacy-led provision of contraception. *BMJ Sex Reprod Health* 2019;**45**:183–9. <https://doi.org/10.1136/bmj.srh-2018-200252>

## REFERENCES

45. Glasier A, Scorer J, Bigrigg A. Attitudes of women in Scotland to contraception: a qualitative study to explore the acceptability of long-acting methods. *J Fam Plann Reprod Health Care* 2008;**34**:213–17. <https://doi.org/10.1783/147118908786000497>
46. Bullard KA, Edelman AB, Williams SM, Rodriguez MI. Ulipristal acetate compared to levonorgestrel emergency contraception among current oral contraceptive users: a cost-effectiveness analysis. *Contraception* 2019;**100**:222–7. <https://doi.org/10.1016/j.contraception.2019.05.004>
47. BBC News. *Boots apologises for morning-after pill response*. 2017. URL: [www.bbc.co.uk/news/uk-40689763](http://www.bbc.co.uk/news/uk-40689763) (accessed April 2021).



# Appendix 1 Supplemental table

TABLE 16 Process evaluation data integration table

Source	Implementation	Mechanisms of impact	Context
Qualitative interviews	<p>Provider acceptability: bridging seen as an important method of developing pharmacy services, overcoming access barriers and reducing EC use. EC consultation opportune time for intervention</p> <p>Concerns raised: additional time/workload pressures; fit with existing practices/guidelines</p> <p>Training: study staff approachable and clear; venue, composition and timing suitable; content and resources adequate. Most felt that training prepared them for delivery, but could have benefited from pharmacist expertise and role-play and refresher sessions. SRH staff received no formal training so lacked awareness of study</p> <p>Barriers to participation: research barriers (e.g. confidentiality of data, paperwork); uncertainty about bridging; common barriers included lack of time/embarrassment; and not wanting to take POP/hormonal contraception. Suggestions to alleviate barriers: option to return/book appointments; more contraception options</p> <p>Fidelity of delivery (pharmacy): descriptions suggest adherence to protocol, although some fatigue with process. Participants mostly reported positive experiences and clear/consistent information about accessing further contraception. Confusion regarding the study aim was common and there were some inconsistencies relating to the rapid-access component</p>	<p>Being approached acted as 'prompt to change contraceptive practices'. Helped to overcome existing barriers (avoidance, lack of time and difficulties accessing appointments)</p> <p>Pharmacy setting accessible, convenient and less embarrassing compared with traditional settings. Other benefits: increased awareness/knowledge of contraception/services and improved confidence in accessing and using contraception</p> <p>Participants currently on effective contraception: had positive/no side effects; found it easy to access further contraception; familiarity. Some on effective contraception post study had no prior experience on contraception (due to lack of need and access barriers), whereas a small number had previous negative experiences and found POP suitable</p> <p>Participants not on effective contraception because of a range of reasons: personal circumstances (e.g. not sexually active, no partner, pregnant or planning pregnancy); worries and experiences of side effects (e.g. prolonged bleeding, mood changes, skin problems); commitment because of busy schedules/forgetting; difficulties accessing GP/SRH clinics or finding time to attend. Side effects from HC commonly mentioned as barrier post study and pre study. Twenty-two women interviewed said they were not on contraception pre study because of previous negative experiences.</p>	<p>Pharmacy context: existing challenges common across sites included competing priorities, high workloads, lack of resources and expanding roles. Pressures exacerbated at particular times (e.g. in winter, flu clinics take priority). Existing challenges had an impact on delivery, with deprioritisation of screening at busy times. New contraceptive guidelines regarding ulipristal acetate acted as a barrier to delivery for some and concerns were raised about future implementation. Despite challenges, pharmacists were typically positive about embedding bridging as a service</p> <p>SRH context: existing challenges across sites included lack of resources, funding cuts and changing service provision. Services being cut and reshaped (two sites moved to providing walk-in consultations only to those who were triaged as a priority). Focus moved away from provision of routine contraception to young people and specialised services. Some worried that participants might be turned away/missed because of a lack of fit with practice priorities and a lack of resources. Some suggested sending to general practices instead</p> <p>Broader cultural context: most participants did not express being consciously aware of any media coverage about contraceptives. Participants mostly described seeing coverage relating to the new male contraceptive pill, and articles focusing on negative side effects and general 'horror stories'. Some did talk about media</p>

continued



TABLE 16 Process evaluation data integration table (continued)

Source	Implementation	Mechanisms of impact	Context
Quantitative data (4-month survey; screening logs)	Fidelity of delivery (SRH centre): few encountered any Bridge-it study participants. Participants mostly described negative experiences (4/5 struggled to get further contraception), reporting lack of awareness, being advised to attend a general practice and clinics being too busy	Not being able to get further contraception through pharmacies was a barrier. Embarrassment/shame of accessing contraception from SRH clinics commonly mentioned	coverage leading to particular contraceptives potentially getting negative reputations and how this could impact on decision-making around contraception
	Fidelity of delivery: 90% ( $n = 178$ ) of intervention participants and 64% ( $n = 134$ ) of control participants provided with information about accessing further contraception. Fifty-four intervention participants could not recall being given a rapid-access card. Most were seen at SRH clinic in < 1 hour (15/25). Sixty-four per cent (16/25) had smooth experiences of the rapid-access system to study SRH clinic	Uptake of effective contraception: 62% (122/198) of intervention participants remained on effective contraception at 4-month follow-up – POP, 36% (71/198); combined pill/patch/ring, 14% (28/198); and LARC methods, 7% (13/198). Forty-four per cent (88/198) of intervention participants were not on effective contraception at 4-month follow-up	
	Acceptability: most women accessed further contraception through their GP (74/141) (vs. from SRH, 21/141). Only 17% of women attended the participating SRH centre and 50% preferred accessing contraception from a GP. Thirty-two per cent of women were not provided with their preferred method of contraception	Reasons for not using effective contraception at 4 months: not currently sexually active, 47% (27/57); worries about side effects, 21% (12/57); not decided on method to use, 16% (7/57); difficult to get appointment with GP or a SRH clinic, 14% (8/57); and difficult to find time to get to GP or a SRH clinic, 11% (6/57)	
	Barriers to participation (screening logs): not willing to give contact details and be followed up (54%, 264/490); not willing to give identifying data sufficient to allow data linkage with NHS registries (54%, $n = 262$ ); already using a hormonal method of contraception (32%, $n = 156$ ); does not require EC (19%, $n = 93$ ); and does not have capacity to give informed consent (13%, $n = 64$ )	Eighteen per cent (35/198) of women did not use any POP because of worries about side effects (29%, 10/35); they were not with a regular partner (23%, 8/35); they did not require regular contraception (20%, 7/35); or they preferred to start another contraceptive (17%, 6/35)  For those who took POP, main reason for stopping before supply ran out: side effects (25%, 40/158) and started another method (4%, 6/158)  Ten per cent (20/198) of intervention participants had used EC post study vs. 18% (37/208) of control participants	

TABLE 16 Process evaluation data integration table (continued)

Source	Implementation	Mechanisms of impact	Context
Training observations and pharmacy selection	<p>Location/format of training: most (n = 27) training conducted in pharmacies (e.g. consultation/training/break rooms) and seven were at SRH sites. On average, one to three pharmacists were present. Training lasted approximately 75–80 minutes</p> <p>Fidelity: consistency across sites, sessions mostly delivered as per training guidance, covering all components. Some adaptations were made, mostly relating to contextual factors (e.g. lack of time) that had an impact on particular components</p> <p>Acceptability: majority of pharmacists appeared enthusiastic about the study and engaged well with content, asking for clarification if unsure. Most seemed confident and accepting of their role. Implementation concerns included lack of staff/resources, volume of paperwork and availability of rapid-access appointments</p> <p>Barriers to participation highlighted in training: reluctance to take POP, lack of time and worries about data confidentiality (particularly from younger participants)</p> <p>Pharmacy selection/recruitment: initially approached those dispensing &gt; 30 ECs per month, but adapted to consider those dispensing &lt; 30 ECs per month to include more independent pharmacies/increase recruitment</p> <p>Barriers to selection: low EC dispensing, charging for EC, commissioned for bridging, lack of interest and too busy</p>	<p>Pharmacists' perspectives: sought-after service, real demand for easier access through pharmacies, often have patients looking for this service</p> <p>Highlighted additional benefits: raising awareness of local sexual health clinics and awareness of testing services</p>	<p>Training sessions, at times, provided insights into other contextual factors that may influence implementation, including the specific pharmacy context, typical clientele and current EC practice/changing guidelines. Pharmacists frequently mentioned high workloads, lack of resources and reliance on locums as potential barriers to delivery</p>

continued

TABLE 16 Process evaluation data integration table (*continued*)

Source	Implementation	Mechanisms of impact	Context
Monitoring of contemporaneous events/changing guidelines	Contraceptive guidelines: March 2018 – new EC guidelines recommending ulipristal acetate (ellaOne) as first option. If this was provided, then the woman was no longer eligible for study. October 2018 – new weight guidance requiring double dose of LNG if weight > 75 kg		Media coverage of contraception: July 2017–December 2019 – 736 articles identified from mainstream media sources. Topics included personal accounts of negative experiences; emerging contraceptive methods (e.g. male contraceptives, contraceptive digital applications); accessibility of contraception (e.g. barriers to access and use); contraceptive behaviour trends; and general informative pieces. Sustained coverage on negative side effects and personalised ‘horror stories’ detailing fatal or life-threatening impacts. Over the 3-year study period, the number of articles almost tripled, from 35 in 2017 to 94 in 2019. A prominent and relevant story during the study was the widespread coverage relating to the cost and accessibility of the pill in a major chain pharmacy in the UK ( $n = 64$ ), which was criticised for refusing to reduce EC cost for fear of ‘incentivis[ing] inappropriate use’. <sup>47</sup> The pharmacy subsequently said it ‘sincerely’ apologised for its ‘poor choice of words’ over emergency contraception pricing <sup>47</sup>
Researcher fieldnotes/meeting minutes	Initial set-up took longer than anticipated, which had consequences for project staffing, pharmacy set-up, training and recruitment. Finalising PGDs and SS for each site was time-consuming and problematic, complicated by differences in health boards. Other factors contributing to delays included changing data protection laws, difficulties organising training sessions, particularly in busy periods, and research staffing issues  Research nurses from all sites reported receiving few e-mail responses and having to spend a substantial amount of effort on the ground to encourage pharmacists to		Pharmacists reported a decline in EC requests during the summer and winter holidays, particularly pronounced in areas normally densely populated by students  Slow recruitment was fuelled by understaffing, reliance on locums and other operational challenges (e.g. prioritisation of flu clinics)  Protocol amendment submitted to allow new weight guidance to be part of study; however, changing guidance did cause some confusion and some pharmacists continued to exclude potential participants based on this new guidance

TABLE 16 Process evaluation data integration table (continued)

Source	Implementation	Mechanisms of impact	Context
	recruit, retrain and assist with paperwork. Reported evident fatigue with research process		Owing to commissioning of a SRH bid, KCH site stopped recruiting and participating pharmacies were removed from the study
	Some major London pharmacies were already commissioned for oral bridging		
Interpretation and synthesis	The intervention was acceptable to providers and was seen as an important way to improve access to contraception and to reduce repeat EC use. Training was considered to be satisfactory, although suggested improvements included drawing on pharmacist expertise, more practice-based learning and formal refresher training. Pharmacists seemed accepting of their role in the study and felt prepared for delivery, although some had concerns relating to workload pressures. Fidelity of delivery was mostly achieved in the pharmacy context, with typically clear and consistent messaging around accessing further contraception. Accounts highlighted a lack of awareness in SRH centres and participants reported unsatisfactory experiences, indicating the need for greater integration of all services involved. A variety of barriers to participation were highlighted, some specific to the research context and others relevant to wider implementation (e.g. embarrassment, reluctance to take POP)	Bridging may have a positive impact on contraceptive practices and knowledge in the short term and potentially longer term. Potential key mechanisms of change highlighted include ease of access, increased knowledge, awareness and confidence in accessing contraception and managing risk. A key mechanism specific to the pharmacy setting was ease of access. Accounts highlighted the real need and demand for this service, suggesting synergy in intervention design and patient need. Persistent barriers to accessing and regularly using routine contraception remain, including worries about side effects, ingrained stigma of SRH services and difficulties accessing contraceptive appointments. Although the study was effective for some (including non-users and previous users), it was not a comprehensive solution and the remaining challenges highlight the need for a package of solutions to ensure that their diverse range of needs are met	A broad range of contextual factors influenced the implementation of the study, including the context of participating pharmacies and SRH centres, broader policy and cultural factors, and the research context. Existing challenges in provider contexts, including lack of resources and changing practice priorities, influenced the implementation of the study, with screening deprioritisation and participants being missed or turned away from SRH centres. Such existing challenges meant a high level of in-person study support was required to motivate staff to recruit. Despite challenges, pharmacists were enthusiastic about embedding bridging as routine practice; however, accounts highlight the need for additional resources because of existing time pressures. There was sustained negative media coverage of contraception during the study, which may have had an impact on decision-making around participating and contraceptive use. Updated contraceptive guidance had an impact on recruitment to the study and has potential implications for wider implementation in the current format
Key learning and recommendations	Suggestions to increase uptake of bridging contraception in the pharmacy setting and overcome barriers to participation include greater advertising and promotion of the service; provision of non-judgemental and supportive contraceptive consultations; an option to book routine contraceptive consultations in pharmacies	Suggestions to increase continued uptake of effective contraception include clear and consistent information provision regarding further contraceptive access, greater linkage with general practices, easier processes for obtaining repeat prescriptions and consideration of longer-term contraceptive care within the pharmacy setting	Existing contextual challenges in the pharmacy and SRH context, including lack of resources and changing practice priorities, highlight the need for sufficient resources and time to administer this service for bridging to be embedded in routine practice

continued

TABLE 16 Process evaluation data integration table (*continued*)

Source	Implementation	Mechanisms of impact	Context
	<p>outside of EC consultations; and increasing the bridging contraceptive options available</p> <p>Learning for future trials: need for streamlined process with condensed paperwork, adequate staff for in-person support, and integration and regular communication with all services involved in implementation and delivery</p>		<p>Challenges in study set-up and implementation highlight the importance of flexibility and adaptability, and the importance of in-person support from study staff throughout</p>
HC, hormonal contraception; KCH, King's College Hospital; SS, Service Specification.			

## Appendix 2 Process evaluation topic guides



### Bridge it Process Evaluation – In depth Interview Guides

#### Pharmacists – Topic Guide

##### Introduction

Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; remind participant they can withdraw at any time or choose not to answer any question.

##### General background (1)

- Age
- Professional backgrounds (*probe: length of service as pharmacist and in current pharmacy*)
- Previous training in similar interventions

##### Pharmacy information (2)

- Description of pharmacy (*probe: size, type, location, services provided, typical day, working conditions; challenges*)
- Description of typical EC provision in pharmacy and local area (*probe: scope of distribution/activity, challenges; gaps; potential improvements*)
- Pharmacists' perceptions of women requesting EC (*probe: typical clientele, positives, negatives*)

##### Clarity and consistency of training and Bridge it intervention materials (3)

- How were you trained for the study?
- How did you find the training? (*probe: positives, negatives, gaps, potential improvement*)
- What are your views on the training manual? (*probe: positives, negatives, gaps, potential improvement*)
- Confidence in delivering the Bridge it intervention and adhering to the protocol/training manual (*probe: positives, negatives, gaps, challenges, concerns*)
  - How well do you think the training prepared you for delivering the Bridge-it intervention? Could it have prepared you more?

- Were you confident that you would be able to deliver the intervention as asked, or did you have any concerns?

#### **Intervention delivery (4)**

- Experiences of delivering the intervention and challenges faced (probe standard/intervention phase)
  - Could you tell me about your experiences of delivering the intervention in practice?
  - Has it been more/less difficult than you had imagined it would be?
  - What do you think worked well/hasn't worked well?
  - Barriers/facilitators to delivering the intervention (*probe: positives, negatives, gaps, potential improvement*)
  - Could you describe any support you received from study staff?
- Consistency in delivering the Bridge it intervention and adhering to the protocol/training manual (*probe: If not, when, and why not?*)
- Describe how the intervention was introduced and delivered in practice
  - How did you find screening as a process? (*probe: barriers/facilitators*)
  - What was your decision-making process relating to approaching individual women about the intervention? Did you approach all/only some? Why?
  - Did you develop a pattern in how you approached recruitment and the paperwork involved?
  - How did you find using the database?
  - On average, how long did the whole process take?
- From your perspective, how well did the Bridge it intervention fit in with day-to-day pharmacy service provision?
- How well did it fit with current pharmacy guidelines for EC distribution?
- Did it raise any unexpected issues relating to day-to-day pharmacy service provision?

#### **Women's response to the Bridge it intervention (5)**

- Perceived facilitators/barriers to women's participation in the Bridge it study (probe standard care/intervention phase)
  - Were women receptive towards the study? Why? Why not?
  - What do you think facilitated participation in the study?
  - What do you think prevented participation?
  - How do you think we could improve participation?
- What, if any, positive effects do you think the Bridge it intervention had?
- What, if any, negative effects do you think the Bridge it intervention had?

**Acceptability of the intervention (6)**

- What were your reasons for taking part in the intervention?
- What, if anything, did you find particularly positive about being involved in the Bridge it study?
- What, if anything, did you find particularly negative about being involved in the Bridge it study?
- Would you volunteer again for a similar role in the future? [*Probe: why?*]
- How could we improve the pharmacist role?
- Suggested changes to the Bridge it intervention if it were to be more widely implemented?

**Other (7)**

- Have you been aware of any relevant media coverage around contraception?
- Are you aware of any changing pharmacy guidelines/policy that may impact the study/future EC provision?

**Closing**

- Provide summary of interview discussion
- Ensure interviewee has opportunity to add comments/ask questions
- Seek feedback on the interview experience



## **SRH Providers – Topic Guide**

### **Introduction**

Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; remind participant they can withdraw at any time or choose not to answer any question.

### **General background (1)**

- Tell me a little bit about your professional background (*probe: current role etc*)
- Previous involvement in similar interventions

### **SRH centre information (2)**

- Could you tell me a bit more about the SRH service you work in? (*probe: size, location, clientele, services provided, typical day, working conditions, challenges*)
- Description of typical EC/contraceptive provision in SRH service and local area (*if not covered*) (*probe: scope of distribution/activity, existing challenges; gaps; potential improvements*)
- Perceptions of women requesting EC (*probe: typical clientele, positives, negatives*)

### **The next set of questions focus on the Bridge-it study**

#### **Awareness of the Bridge it intervention (3)**

- How did you find out about the Bridge-it study?
- What are your thoughts on the Bridge-it study? [*Probe: positives, negatives, gaps, potential improvement*]

#### **Experiences of Bridge-it intervention and challenges faced (4)**

- Could you tell me a bit about your experiences so far relating to the Bridge-it study?
- From your perspective, how well does the Bridge it intervention fit in with day-to-day SRH service provision?
- Has it raised any unexpected issues/challenges?
- What do you think has worked well?
- How do you think this could be improved?
- Was there support from within your workplace?

#### **Women's response to the Bridge it intervention (5)**

- From your perspective, did women attend SRH service after attending the pharmacy for EC?
  - Did Bridge it participants attending SRH for follow up bring their Bridge it study card with them?

- Had participants used their POP supply (probe: If not, when not and why not?)
- Do you think women generally were receptive towards the study? Why? Why not?
- Do you think there are any ways we could improve participation?
- Did Bridge it participants start effective contraception at SRH? (*probe: If not, when not and why not?; barriers/challenges to uptake of effective contraception*)
- What, if any, positive effects do you think the Bridge it intervention had? (*probe: on the service, on women*)
- What, if any, negative effects do you think the Bridge it intervention had? (*probe: on the service, on women*)

### Acceptability of the intervention (6)

- What, if anything, did you find particularly positive about being involved in the Bridge it study?
- What, if anything, did you find particularly negative about being involved in the Bridge it study?
- How could we improve the SRH service provision role?
- Suggested changes to the Bridge it intervention if it were to be more widely implemented?

### Other (7)

- Were you aware of any relevant media coverage related to contraception that might have influenced participation in the study/attitudes to contraception?
- Are you aware of any changing policy/guidelines that might impact your service/future contraceptive provision?

### Closing

- Provide summary of interview discussion
- Ensure interviewee has opportunity to add comments/ask questions
- Seek feedback on the interview experience

## **Bridge it Participants – Topic Guide**

### **Introduction**

Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; remind participant they can withdraw at any time or choose not to answer any question.

### **General background (1)**

- Age
- Life circumstances (i.e. relationships, family etc)
- Area of residence, who living with (ie. family, partner, friends, homeless)
- Employment/education

### **Contraceptive use (2)**

- The wider context of their lives and experiences of using EC/contraception
  - Previous experience of EC use/unprotected sex (before/after EC use)
  - Previous contraceptive use
  - Previous pregnancies/abortions
- Decision making process – what kind of things have influenced your contraceptive use, what did you consider when making decisions about contraceptive use?
- Influence of others (i.e. family, friends, healthcare providers etc)

### **Request for EC (3)**

- Do you mind telling me a bit about why you requested EC at the time of recruitment to the Bridge it study (*probe: unprotected sex, contraceptive failure, unplanned sex*)
- Decision making process – what factors considered in deciding to use EC?
- Influence of others (i.e. family, friends, healthcare providers etc)
- Decision to attend the pharmacy to request EC – what factors considered in deciding to use EC?
- Why that particular service/pharmacy?

### **Recruitment to the Bridge it study (4)**

- How were you recruited into the study?
- What did you understand about why we were doing the study?
  - *What it was about?*
  - *Why you were invited to take part?*
- Did you understand what would be involved in taking part?

- What information did the pharmacist provide you with about taking part in the study?  
(probe: verbal, written, other? Was it clear?)

### Reflections on experience of participating in the intervention in pharmacy (5)

- What information did the pharmacist provide you with about starting contraception after EC? (probe: verbal, written, other?)
- What information did the pharmacist provide you with about where to get contraception after EC? (probe: verbal, written, other?)
- What information did the pharmacist provide you with about using the supply of the POP? (probe: verbal, written, other)
- What information did the pharmacist provide you with about using the 'study card' that participants show at the local sexual health clinic to get a quick appointment? (probe: verbal, written, other)

### Reflections on experience of using EC/POP (6)

- Experience of using the EC that the pharmacist gave you (probe: positives, negatives, when?)
- Experience of using the POP that the pharmacist gave you (probe: positives, negatives, when/for how long? If stopped or didn't take it, why?)
- Decision making process – what factors considered in deciding to use/not to use POP?
- Influence of others (i.e. family, friends, healthcare providers etc)

### Reflections on experience of accessing SRH service (7)

- Did you attend SRH service after attending the pharmacy for EC?
  - Did you take your Bridge it study card with you? (probe: If not, why not?)
  - What was your experience of the rapid access appointment? (probe: positives, negatives, potential improvement)
- Decision making process – what factors considered in deciding to attend SRH service?
- Influence of others (i.e. family, friends, healthcare providers etc)
- What information did the SRH provider provide you with about starting effective contraception? [probe: verbal, written, other?]
- Did you start your preferred method of contraception at SRH? (probe: If not, why not)

### Subsequent contraceptive use (8)

- Are you still using the method of contraception you received at SRH/GP? (probe: If not, why not)

- From your perspective, what are the barriers/challenges to uptake of effective contraception?

#### **Acceptability of the intervention (9)**

- What, if anything, did you find particularly positive about being involved in the Bridge it study?
- What, if anything, did you find particularly negative about being involved in the Bridge it study?
- Did the intervention prompt any change and/or any negative or unintended consequences for you? (*probe: Any negative outcomes, difficulties, challenges?*)

#### **Implementing the Bridge it intervention (10)**

- From your perspective, how well did the Bridge it intervention fit in with your day-to-day life?
- Did it raise any unexpected issues relating to your day-to-day life?
- How could we improve the Bridge it intervention if it were to be more widely implemented?

#### **Other (11)**

- Were you aware of any media coverage around contraceptive use/pharmacies? (a)
- Are there any other issues regarding the Bridge it study that you would like to talk about?

#### **Closing**

- Provide summary of interview discussion
- Ensure interviewee has opportunity to add comments/ask questions
- Seek feedback on the interview experience

## Appendix 3 Baseline questionnaire

### Baseline Questionnaire

We would be very grateful if you would spend some time filling out this confidential questionnaire. It should take you about 5 minutes. The questionnaire asks about your background, pregnancy and previous use of contraception. Completion of this is voluntary and you don't have to answer this questionnaire or any question in it if you don't want to – it is entirely your choice.

**Q1. What is your date of birth?** \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy)

**Q2. Tick all the methods of contraception that you have ever used:**

- ☐ **Combined hormonal contraceptive pill/ patch or ring i.e. contain two hormones e.g. Microgynon, Ovranette, Evra patch, Nuvaring**
- ☐ **Progestogen only pill (mini pill) e.g. Cerazette, Noriday**
- ☐ **Male condom**
- ☐ **Contraceptive injection' jab' (Depo Provera or Sayana)**
- ☐ **Implant (Nexplanon)**
- ☐ **Copper Coil/intra-uterine device (IUD)**
- ☐ **Intrauterine system (Mirena or Jaydess or IUS)**
- ☐ **Female condom**
- ☐ **Cap/diaphragm**
- ☐ **Partner has been sterilised (vasectomy)**
- ☐ **I have been sterilised**
- ☐ **Withdrawal method**
- ☐ **Natural family planning (monitoring of temperature, calendar, urine tests etc)**
- ☐ **Other method of protection (please say what) .....**
- ☐ **I have never used any method**

**(Please tick)**

**Q3. Have you ever given birth?** ☐ **Yes** ☐ **No**

**Q4. Have you ever had a termination (abortion)?** ☐ **Yes** ☐ **No**

**Q5. Have you ever had a miscarriage?** ☐ **Yes** ☐ **No**

**Q6. Have you ever an ectopic pregnancy?** ☐ Yes ☐ No

**Q7. Are you in an ongoing sexual relationship with a man?**

☐ Yes ☐ No ☐ Unsure

**Q8. Is this the first time you have taken the emergency contraceptive pill?  
(please tick box)**

☐ Yes

☐ No please state number of times taken in the last 12 months .....

**Q9. Which of the following best describes your ethnic background? (please tick box)**

☐ White (UK, Irish or any other white background)

☐ Asian or Asian British (Bangladeshi, Indian, Pakistani or any other Asian Background)

☐ Black or Black British (African, Caribbean or any other Black background)

☐ Mixed or any other ethnic background (please say what) .....

**Thank you for taking the time to complete this questionnaire. Your participation is much appreciated.**

**Please indicate how you would like to receive your £10 voucher:**

☐ By phone (please insert number).....

☐ By email (please insert email).....

☐ By post (please insert address).....

## Appendix 4 Four-month questionnaire for control group



--	--	--	--	--

### Telephone interview- CONTROL

Name of interviewer..... Date of  
1st call (dd/mm/yy)....

Comment: no answer/left message/text sent requesting call back/other

**Date of 2<sup>nd</sup> call (dd/mm/yy)**

Comment: no answer/left message/text sent requesting call back/other

**Date of 3<sup>rd</sup> call (dd/mm/yy)\***

Comment: no answer/left message/text sent requesting call back/other Date of

interview (dd/mm/yy).....

### Instructions for research nurse:

- Verify that the person answering the telephone is the correct individual
- Introduce yourself; say that you are the research nurse for the Bridge-it study
- Remind the participant what project is about and tell her that this is a short telephone interview (approx. 10 mins)
- Check that she is still willing to participate.
- Remind her that she is under no obligation to answer any or all of the questions
- Say that you are very grateful for her help.
- Check that it is a convenient time for her to speak. If not rearrange a suitable date/time. (Re- scheduled for (dd/mm/yy)..... @.....hrs)

### At END of interview:

- Thank her for participating
- Remind her of the study website details where results of study will be posted
- Ask if she would like a copy of results of the study at the end
- verify whether by text/email/postal address (select)
- Check that you have the most up to date phone/email/postal address





--	--	--	--	--

- Check if she consented to the detailed telephone interview (60 mins) : still willing to participate in the telephone interview?

☐ No      ☒ Yes

Best time to be contacted?

	Any time	Morning (9am-12 noon)	Afternoon (12 noon-5pm)	Evening (5-8pm)
Weekday	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Weekend	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



--	--	--	--	--

## 4 Month Questionnaire - CONTROL

We would be very grateful if you would spend some time filling out this anonymous questionnaire. It should take you about 10 minutes. Completion of this is voluntary and you don't have to answer this questionnaire or any question in it if you don't want to – it is entirely your choice.

### Section A. Information at the pharmacy and contraception

*1. What method of contraception (if any) were you using at the time when you went to get EC from the pharmacy ? (Please tick)*

☐ None

☐ Condoms

☐ Other (please write it here).....

*2. Did you take the EC that the pharmacist gave you?*

☐ Yes

☐ No

☐ If No, (please tell us why not).....

*3. Did the pharmacist provide you with any information about starting contraception after EC? (Please tick)*

☐ No

☐ Verbal information only

☐ Written information only

☐ Both written and verbal information

*4. Did the pharmacist provide you with any information about where to get contraception ? (Please tick)*

☐ No

☐ Verbal only

☐ Written only

☐ Both written and verbal

*5. What method or methods of contraception (if any) are you using now? (Please tick all that apply)*



--	--	--	--	--

- ☐ Combined hormonal contraceptive pill/patch or ring
- ☐ Progestogen only pill (mini pill)
- ☐ Male condom
- ☐ Contraceptive injection 'jag' (Depo Provera or Sayana)
- ☐ Implant (Nexplanon)
- ☐ Copper Coil/intra-uterine device (IUD)
- ☐ Intrauterine system (Mirena or Jaydess)
- ☐ Female condom
- ☐ Cap/diaphragm
- ☐ Partner has been sterilised (vasectomy)
- ☐ I have been sterilised
- ☐ I am currently pregnant
- ☐ Other method of protection-**please write here what this is** .....
- ☐ I am not using any method of contraception (**Please go to question 8**)

**6. When did you start using this/these contraceptive method(s)?**  
(Please tick)

- ☐ The same day that I took the EC
- ☐ The day after I took the EC
- ☐ With the start of my next period after the EC
- ☐ Other – please specify the approximate date (dd/mm/yyyy)

**7. Where did you get the current method(s) of contraception that you are using from**  
(Please tick all that apply)

- ☐ GP clinic
- ☐ Family planning/ sexual health clinic

☐ Other -please tell us where you got contraception from.....

Please go to question 9 now

**8. Please tell us why you are not using a method of contraception? (Please tick all that apply)**

- ☐ Not currently sexually active
- ☐ I am worried about side effects with contraception
- ☐ I cannot use contraception due to medical reasons
- ☐ I am not decided on what method I want to use
- ☐ Difficult to get an appointment for GP or family planning/sexual health clinic appointment
- ☐ Difficult to find time to get to GP or family planning/sexual health clinic appointment
- ☐ I am trying for a baby
- ☐ Other - please tell us why.....



--	--	--	--	--

9. Have you used EC any further time(s) since entering the study? (Please tick)

☐ No

☐ Yes- please tell us how many times approximately .....

10. Have you been pregnant since you entered the study 4 months ago?

☐ No (Go to question 17)

☐ Yes

if Yes, please tell us about all of the pregnancies you have had since you entered the study 4 months ago (Please tick all that apply)

☐ I am currently pregnant

☐ I had a miscarriage

☐ I had an abortion

☐ I had an ectopic

☐ Other - please tell us .....

11. Below are some questions that ask about your circumstances and feelings around the time you became pregnant. Please think of your current (or most recent) pregnancy when answering the questions below.

**In the month that I became pregnant.....**

**(Please tick the statement which most applies to you):**

☐ I/we were not using contraception

☐ I/we were using contraception, but not on every occasion

☐ I/we always used contraception, but knew that the method had failed (i.e. broke, moved, came off, came out, not worked etc) at least once

☐ I/we always used contraception

12. In terms of becoming a mother (first time or again), I feel that my pregnancy happened at the.....

**(Please tick the statement which most applies to you):**

☐ right time

☐ ok, but not quite right time

☐ wrong time

13. Just before I became pregnant.....

**(Please tick the statement which most applies to you):**



--	--	--	--	--

I intended to get pregnant  
 My intentions kept changing  
 I did not intend to get pregnant

**14. Just before I became pregnant...**

*(Please tick the statement which **most** applies to you)*

I wanted to have a baby  
 I had mixed feelings about having a baby  
 I did not want to have a baby

*In the next question, we ask about your partner - this might be (or have been) your husband, a partner you live with, a boyfriend, or someone you've had sex with once or twice.*

**15. Before I became pregnant...**

*(Please tick the statement which **most** applies to you)*

My partner and I had agreed that we would like me to be pregnant  
 My partner and I had discussed having children together, but hadn't agreed for me to get pregnant  
 We never discussed having children together

**16. Before you became pregnant, did you do anything to improve your health in preparation for pregnancy?**

*(Please tick **all** that apply)*

Took folic acid  
 ➤ Stopped or cut down smoking  
 Stopped or cut down drinking alcohol  
 Ate more healthily  
 Sought medical/health advice  
 ➤ Took some other action, please describe ..... or  
 I did not do any of the above before my pregnancy



--	--	--	--	--


*17. Have you had any hospital admissions in the last 4 months since you participated in the Bridge-it study? (Please tick)*

☐ No

☐ Yes

If you have answered yes to this question, then the study research will need to call you to get more details.

Please return this questionnaire in the envelope provided to:





## Appendix 5 Four-month questionnaire for intervention group



--	--	--	--	--

### Telephone interview - INTERVENTION

Name of interviewer..... Date of  
1st call (dd/mm/yy)....

Comment: no answer/left message/text sent requesting call back/other

**Date of 2<sup>nd</sup> call (dd/mm/yy)**

Comment: no answer/left message/text sent requesting call back/other

**Date of 3<sup>rd</sup> call (dd/mm/yy)\***

Comment: no answer/left message/text sent requesting call back/other Date of

interview (dd/mm/yy).....

### Instructions for research nurse:

- Verify that the person answering the telephone is the correct individual
- Introduce yourself; say that you are the research nurse for the Bridge-it study
- Remind the participant what project is about and tell her that this is a short telephone interview (approx. 10 mins)
- Check that she is still willing to participate.
- Remind her that she is under no obligation to answer any or all of the questions
- Say that you are very grateful for her help.
- Check that it is a convenient time for her to speak. If not rearrange a suitable date/time. (Re- scheduled for (dd/mm/yy)..... @.....hrs)

### At END of interview:

- Thank her for participating
- Remind her of the study website details where results of study will be posted
- Ask if she would like a copy of results of the study at the end
- verify whether by text/email/postal address (select)
- Check that you have the most up to date phone/email/postal address





--	--	--	--	--

- Check if she consented to the detailed telephone interview (60 mins) : still willing to participate in the telephone interview?

☐ No      ☐ Yes

Best time to be contacted?

	Any time	Morning (9am-12 noon)	Afternoon (12 noon-5pm)	Evening (5-8pm)
Weekday	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Weekend	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



--	--	--	--	--

## 4 Month Questionnaire - INTERVENTION

We would be very grateful if you would spend some time filling out this anonymous questionnaire. It should take you about 10 minutes. Completion of this is voluntary and you don't have to answer this questionnaire or any question in it if you don't want to – it is entirely your choice.

### Section A. Information at the pharmacy and contraception

*1. What method of contraception (if any) were you using at the time when you went to get EC from the pharmacy? (Please tick)*

- ☐ None
- ☐ Condoms
- ☐ Other (please write it here).....

*2. Did you take the EC that the pharmacist gave you?*

- ☐ Yes
- ☐ No
- ☐ If No, (please tell us why not).....

*3. Did the pharmacist provide you with any information about starting contraception after EC? (Please tick)*

- ☐ No
- ☐ Verbal information only
- ☐ Written information only
- ☐ Both written and verbal information

*4. Did the pharmacist provide you with any information about where to get contraception ? (Please tick)*

- ☐ No
- ☐ Verbal only
- ☐ Written only
- ☐ Both written and verbal

*5. What method or methods of contraception (if any) are you using now? (Please tick all that apply)*



--	--	--	--	--

- ☐ Combined hormonal contraceptive pill/patch or ring
- ☐ Progestogen only pill (mini pill)
- ☐ Male condom
- ☐ Contraceptive injection 'jag' (Depo Provera or Sayana)
- ☐ Implant (Nexplanon)
- ☐ Copper Coil/intra-uterine device (IUD)
- ☐ Intrauterine system (Mirena or Jaydess)
- ☐ Female condom
- ☐ Cap/diaphragm
- ☐ Partner has been sterilised (vasectomy)
- ☐ I have been sterilised
- ☐ I am currently pregnant
- ☐ Other method of protection-**please write here what this is** .....
- ☐ I am not using any method of contraception (**Please go to question 8**)

**6. When did you start using this/these contraceptive method(s)?**  
(Please tick)

- ☐ The same day that I took the EC
- ☐ The day after I took the EC
- ☐ With the start of my next period after the EC
- ☐ Other – please specify the approximate date (dd/mm/yyyy)

**7. Where did you get the current method(s) of contraception that you are using from**  
(Please tick all that apply)

- ☐ GP clinic
- ☐ Family planning/sexual health clinic

☐ Other -please tell us where you got contraception from.....

Please go to question 9 now

**8. Please tell us why you are not using a method of contraception? (Please tick all that apply)**

- ☐ Not currently sexually active
- ☐ I am worried about side effects with contraception
- ☐ I cannot use contraception due to medical reasons
- ☐ I am not decided on what method I want to use
- ☐ Difficult to get an appointment for GP or family planning/sexual health clinic appointment
- ☐ Difficult to find time to get to GP or family planning/sexual health clinic appointment
- ☐ I am trying for a baby
- ☐ Other - **please tell us why** .....



--	--	--	--	--

9. Have you used EC any further time(s) since entering the study? (Please tick)

☐ No

☐ Yes- please tell us how many times approximately .....

10. Have you been pregnant since you entered the study 4 months ago?

☐ No (Go to question 17)

☐ Yes

if Yes, please tell us about all of the pregnancies you have had since you entered the study 4 months ago (Please tick all that apply)

☐ I am currently pregnant

☐ I had a miscarriage

☐ I had an abortion

☐ I had an ectopic

☐ Other - please tell us .....

11. Below are some questions that ask about your circumstances and feelings around the time you became pregnant. Please think of your current (or most recent) pregnancy when answering the questions below.

**In the month that I became pregnant.....**

**(Please tick the statement which most applies to you):**

☐ I/we were not using contraception

☐ I/we were using contraception, but not on every occasion

☐ I/we always used contraception, but knew that the method had failed (i.e. broke, moved, came off, came out, not worked etc) at least once

☐ I/we always used contraception

12. In terms of becoming a mother (first time or again), I feel that my pregnancy happened at the.....

**(Please tick the statement which most applies to you):**

☐ right time

☐ ok, but not quite right time

☐ wrong time

13. Just before I became pregnant.....

**(Please tick the statement which most applies to you):**



--	--	--	--	--

I intended to get pregnant  
 My intentions kept changing  
 I did not intend to get pregnant

**14. Just before I became pregnant...**

**(Please tick the statement which most applies to you):**

I wanted to have a baby  
 I had mixed feelings about having a baby  
 I did not want to have a baby

*In the next question, we ask about your partner - this might be (or have been) your husband, a partner you live with, a boyfriend, or someone you've had sex with once or twice.*

**15. Before I became pregnant....**

**(Please tick the statement which most applies to you):**

My partner and I had agreed that we would like me to be pregnant  
 My partner and I had discussed having children together, but hadn't agreed for me to get pregnant  
 We never discussed having children together

**16. Before you became pregnant, did you do anything to improve your health in preparation for pregnancy?**

**(Please tick all that apply)**

Took folic acid  
 ➤ Stopped or cut down smoking  
 Stopped or cut down drinking alcohol  
 Ate more healthily  
 Sought medical/health advice  
 ➤ Took some other action, please describe ..... or  
 I did not do any of the above before my pregnancy



--	--	--	--


*17. Have you had any hospital admissions in the last 4 months since you participated in the Bridge-it study? (Please tick)*

☐ No

☐ Yes

If you have answered yes to this question, then the study research will need to call you to get more details.

Please return this questionnaire in the envelope provided to:









EME  
HS&DR  
HTA  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***